

CURRICULUM VITAE

Name: William T. Creasman, M. D.
Telephone: Office: (843) 792-4509

Education: Baylor University, B. A., 1952-56
Baylor University College of Medicine, M. D., 1956-60

Internship: Jefferson Davis Hospital, Houston, Texas, 1960-61

Postgraduate Training: Resident, Department of Obstetrics and Gynecology,
University Rochester Medical Center, Rochester, NY,
1963-67
Research Fellow, Department of Obstetrics and Gynecology,
University of Rochester Medical Center, Rochester,
NY 1965
Fellow in Gynecology Oncology, The University of Texas,
M.D. Anderson Hospital and Tumor Institute,
Houston, TX 1967-68
Senior Fellow in Gynecology Oncology, The University of
Texas
M. D. Anderson Hospital and Tumor Institute,
Houston, TX 1968-69

Licensure: Texas 1960
Arizona 1967
North Carolina 1970
South Carolina 1986

Certification: American Board of Obstetrics and Gynecology, 1969
American Board of Gynecologic Oncology, 1974
Recertification in Obstetrics and Gynecology, 1991

Military Service: United States Air Force, Flight Surgeon, 1961-63

Professional Appointments: Instructor, Department of Obstetrics and Gynecology, The
University of Rochester Medical Center, 1966-69
Faculty Associate, Department of Surgery, Section of
Gynecology, The University of Texas, M. D. Anderson
Hospital and Tumor Institute at Houston, 1969
Assistant Professor of Surgery (Gynecology) and Assistant
Gynecologist, Department of Surgery, Section of
Gynecology, The University of Texas M. D. Anderson
Hospital and Tumor Institute at Houston, 1970

Assistant Professor, Department of Obstetrics and Gynecology, Director of Gynecologic Oncology, Duke University Medical Center, 1970
Designated Key Investigator (one of seven), Duke University Comprehensive Center, 1972
Associate Professor, Department of Obstetrics and Gynecology, Director, Oncology Division, Duke University Medical Center, 1973
Professor, Director, Oncology Division, Department of Obstetrics and Gynecology, Duke University Medical Center, 1978-1986
James M. Ingram Professor of Gynecologic Oncology, Duke University Medical Center, 1982-1986
Adjunct Professor, Duke University Medical Center, 1986-1992
Sims-Hester Professor and Chairman, Department of Obstetrics and Gynecology, Medical University of South Carolina, 1986 to 2000
J. Marion Sims Professor of Obstetrics and Gynecology, 2000 to present

Medical & Scientific
Organizations:
Fellow

American College of Obstetricians & gynecologists,
Oncology Committee, District IV, 1973-76
Committee on Gynecologic Practice (Gynecologic Oncology), 1979-1982
Director, Advanced Colposcopy 1982-87
Co-Chairman, Prolog-Oncology, 1985
Chairman, Prolog-Oncology, 1985
Chairman: Task Force on the Role of the
Obstetrician-Gynecologist in Cancer Detection.
International Affairs Committee - Member
Delegate, FIGO Congress, Montreal
District IV
Chairman, Scientific Program, 1991.
Postgraduate faculty, 1991
Stump the Professor, 1994
Speaker, Annual Clinical Meeting, 1992,1995, 1996
Society of Gynecologic Oncologists
Secretary-Treasurer, 1975-78
Local Arrangements Chairman, 1980, 1983
Program Chairman, 1983
Council, 1984-87
President, 1988-89

International Federation Gynecologists and Obstetricians (FIGO)

Chairman, Committee on Gynecologic Oncology, 1985-1996

Editorial Board: Annual Report

Society of Pelvic Surgeons

Local Arrangement Chairman 1982, 1990

Felix Rutledge Society

Council, 1974-76

President, 1976-77

Gynecologic Oncology Group

Executive Committee, 1975-79

Publication Committee, Chairman, 1976-84

Southeastern Liaison Committee, Chairman, 1977

Cancer Control Committee, Subcommittee Chairman, 1976

Protocol Committee, 1975-

Cervix Committee, Co-Chairman, 1974-77

Gyn Management Committee, 1974

Basic Science Committee, Chairman, 1984-1989

Quality Control Chairman, 1990-1995

Membership Committee, 1982-

American Gynecologic and Obstetrical Society

Fellowship Committee, 1989-92

American Joint Committee on Cancer

Gyn curator

SGO representative

American Medical Association

American Radium Society

American Society of Clinical Oncology

Association of Professors of Gynecology and Obstetrics

Member, Executive Education Program

Charleston County Medical Society

Council of University Chairs of Obstetrics and Gynecology

Durham-Orange County Medical Society

North Carolina Medical Society

North Carolina Obstetrical and Gynecological Society

F. Bayard Carter Society of Obstetricians and Gynecologists

Piedmont Obstetrical and Gynecological Society

South Carolina Medical Society

South Atlantic Association of Obstetricians and

Gynecologists

S. C. Obstetrical and Gynecological Society

President, 1993

Thegos

Mid-Atlantic Gynecologic Oncology Society

South Carolina Oncology Society
American Cancer Society, Board of Directors, CHS
Duke Faculty Club
 Vice President, 1977-79
 President, 1978-79
 Council, 1980
Kansas City Gynecological Society (Honorary)
Bellevue Obstetrical and Gynecologic Society, Honorary
 Fellow
D. A. Boyes Society (Honorary)
Texas Association of Obstetricians and Gynecologists
 (Honorary)
Canadian Society of Gynecologic Oncology (Honorary
 Member)

Awards & Honors:

Monroe Award, 1966
Bancroft Pediatric Research Award, 1967
American College of Obstetricians and Gynecologists, Junior
 District VII Award, 1969
 Prize Thesis, South Atlantic Association of
 Obstetricians and Gynecologists, 1971

 President's Award, American College of Obstetricians
 and Gynecologists, 1973
 First Prize Paper, American College of Obstetricians
 & Gynecologists, 1980
Who's Who in America
Who's Who in Medicine
Who's Who in the South
Recognition as one of the top ten gynecologic oncologists in
 the United States, *Town and Country Magazine*,
 1978.
Recognition as one of the best medical specialist in the
 United States, *Town and Country Magazine*, 1984.
Recognition as one of the best physicians for women in the
 United States, *Good Housekeeping Magazine*, 1988,
 1997
Recognition as one of the outstanding medical specialists in
 the U. S., Part I, *Town and Country Magazine*,
 October 1989.
Alpha Omega Alpha (Faculty), Medical University of South
 Carolina, 1989.
Distinguished Alumnus Award, M. D. Anderson Cancer
 Center, 1990

Listed in **Best Doctors in the United States**; Steven Naifeh and Gregory White Smith, Woodward/White, Aiken, SC, 1992, 1994, 1999

Listed in **Best Doctors in the South**; Steven Naifeh and Gregory White Smith, Woodward/White, Aiken, SC

Recognition in *Good Housekeeping* "400 Best Cancer Doctors in America, October 1992.

Recognition of a lifetime contribution towards the improvement of women's health. Presented by International Federation of Gynecology (FIGO), September 1994

Recognized as one of the best doctors in America in *American Health*, 1996

Member, Bonnet Maker Craft of Dundee, Scotland
Trustee, Helene Harris Trust

Inducted as a Fellow ad eundem for the Royal College of Obstetricians and Gynecologists, London, England, September 1997

American College of Obstetricians and Gynecologists District IV Junior Fellow Outstanding Teaching Award, 1997

Manuscript on Hormones and Cancer selected as best paper published in 1997 by *Contemporary Ob/Gyn*

Teaching Professor, Cancer Research Center, Taiwan 1997
Margaret Mead Journalism Award on Postmenopausal Health, 1998.

Distinguished Alumnus Award, Baylor University College of Medicine, 2000

Robert Wood Johnson Foundation award for excellence in end-of-life care textbook content for **Clinical Gynecologic Oncology**, 6th Edition.

International Union Against Cancer TNM Expert Advisory Panel on Gynecologic Cancer, 2001-2007

International Gynecologic Cancer Society for "Excellence in Gynecology"; an award made at the biannual meeting, 2005.

Listed in **America's Top Doctors for Cancer**, Castle Connolly Medical Ltd, New York, NY, 2005

Invited Named
Lectureships and
Invitations
1976

Melville Robertson Memorial Lecture, Dundee, Scotland,

William K. Diehl Memorial Lecture, Baltimore, MD, 1977

Jerome H. Rudolph Memorial Lecture, Rochester, NY, 1981

Invited Lecturer, International Symposium on Current Status
and Future Development in Obstetrics and
Gynecology, Dundee, Scotland, 1981

JPA Latour Lecture, McGill University, Montreal, Canada,
1982

Invited participant, International Symposium, Carcinoma of
the Ovary. Chances for Improving Therapy Results,
Dusseldorf, Germany, 1982.

J. Marion Sims Lecturer, Alabama Association of
Obstetricians and Gynecologists, 1983

Keynote Speaker, Australia and New Zealand Congress of
Obstetricians and Gynecologists, 1985

Distinguished Visiting Professor, Washington University, St.
Louis, Mo. April 30-May 2, 1987.

Invited Speaker, International Symposium on Multiple
Modality Treatment of Ovarian Carcinoma, Genova,
Italy, September 1987

J. Donald Woodruff Guest Lecture, J. Donald Woodruff
Symposium, The Johns Hospital University, 1988.

Herbert G. Winston Lecture in Obstetrics and Gynecology of
the Raymond and Beverly Sochler Foundation

The George H. Rezek Lecture, University of Illinois, College
of Medicine, 1988

Invited Speaker, International Symposium: Operative
Treatment of Cervical and Ovarian Cancer, Graz,
Austria, 1988

Chairman, Ovarian Cancer XXVI World Congress of the
International College of Surgeons, Milan, Italy, 1988.

Faculty, European School of Oncology, Orta, Italy, 1988.

Guest Speaker, Japan Society for Cancer Therapy, Niigata,
Japan 1988

Visiting Professor, Japan, 1988: University of Tokyo; Jikei
Medical College, Kyoshu University Faculty Medicine,
Fukwoke, Keio University

Invited Speaker, Ovarian Cancer Forum, Helen Harris
Memorial Trust, Graz, Austria, 1989

William E. Studdiford Jr. Visiting Professor, NYU

Management of Ovarian Cancer. Invited Participant, 30th
Anniversary, Oncology Hospital, Mexico City

Recent Advances in Gynecologic Oncology, Catholic University Medical College, Seoul, Korea
Invited Moderator on Cervical Cancer, Recent Advances in Gynecologic Oncology, Budapest, Hungary
Invited Moderator on Ovarian Cancer Symposium, 15th International Cancer Conference (UICC) Hamburg
Invited Speaker, Helene Harris Trust, London: Surgical Management of Advanced Ovarian Carcinoma
Invited Speaker, American College of Obstetricians and Gynecologists Annual Meeting, Las Vegas, 1992: (1) Scientific Session Presentation: Practical Management of HPV. (2) Audiovisual Presentation: Maximal Debulking in Ovarian Cancer.
International Operative Tutorial, Berlin Free University, 1992
American Fertility Society, 1992
Controversies in Gyn Oncology; Einstein College of Medicine, 1992
Colorado Ob/Gyn Society, 1992
International Symposium of the Argentine Association of Oncologic Gynecology, 1991
CD Christian Memorial Lecture, University of Arizona 1991
Austrian Gynecology Oncology Group, Vienna, 1992
Visiting Professor, University of Salzburg, 1992
Third Biennial International Forum on Ovarian Cancer, London 1992
American Cancer Society Symposium on Gyn Cancer, 1992
Visiting Professor, University of Missouri, Kansas City, 1991
Pacific Northwest Ob/Gyn Association, 1991
FIGO Congress, Singapore, 1991
Eighth International Symposium on Cancer Research,, Charleston, S.C., 1992
NIH (NCI) Workshop on Cervical Cancer, 1992
Hugh R.K. Barber Ob/Gyn Alumni Society and Residents Research Day, 1992
Obstetrical Society of Philadelphia, 1993
Hilliard Dubou, M.D. Memorial Lecture, New York, 1993
Visiting Professor, Eastern Virginia Medical School, 1993
Visiting Professor, Bowman Gray School of Medicine, 1993
Faculty, European School of Oncology, Uruguay and Argentina, 1994
Visiting Professor, University of South Florida, 1994
Visiting Professor, University of Florida, 1994
Invited participant, NIH Consensus Conference on Ovarian Cancer, 1994
AGO Consensus Meeting: Adjuvant Treatment of Uterine Cancer. University of Freiburg, Germany, 1994

Visiting Professor, UCLA, 1994
Invited speaker, Symposium, University of Puerto Rico
School of Medicine, 1994
Invited speaker, Robert Wood Johnson Medical School
Symposium, 1994
Invited speaker, British Columbia Cancer Center, David
Boyce Symposium, 1994
Visiting professor, Hershey Medical Center, 1995
W. Norman Thornton, Jr. Symposium, University of
Virginia, 1995
Carrol H. Lippard Memorial Lecture, Lynchburg, Virginia,
1995
European School of Oncology, Budapest Hungary 1995
Kendrick-Menaker lecturer, University of Kansas, Wichita,
Kansas, 1995
Invited speaker, Dallas Fort Worth Ob/Gyn Society, 1996
Invited speaker, European School Oncology, Budapest,
1996
Invited speaker, Clinical Science Update Session, ACOG
annual meeting, 1996
Visiting professor, University of Washington, 1996
Invited speaker, District I ACOG, 1996
Invited speaker, Gyn and Obs Congress, Turkey, 1996
Invited speaker, Gyn Oncology Symposium, Chicago, 1996
Visiting Professor, Resident Research Day, New Jersey
Medical School, 1996
Consultant U.S. Army: In progress review for ATLAS project
(Breast Cancer Tamoxifen Study) 1996
Invited Speaker, Philippine Ob/Gyn Society, 1996
FIGO, Copenhagen, Denmark 1997 -- Invited to give
"Screening for Gynecologic Cancers" in the Update
Session.
Alumni Lecture, University of Rochester, 1997
Visiting Professor, Washing University, 1997
Donald Richardson Memorial lecture. ACOG, District IV,
1997
Invited speaker, Spanish National Society for Study of
Menopause, 1998
Kushner Memorial Lecture, Columbia Hospital for Women
Medical Center, 1998
Invited speaker, Hormone and Cancer Symposium,
Salzburg, Austria, 1998
Postgraduate course speaker, ACOG, 1998
Visiting professor, Residents Research Day, Albany Medical
Center, 1998
Visiting Professor, University of Kansas, 1998

Invited speaker, II Latin American Congress on Climacterium and Menopause, 1998

Invited speaker, German Menopause Society, 1998

Invited speaker, Korean Association of Obstetricians and Gynecologists, Seoul, October 1999

Invited speaker, Western North Carolina Cancer Conference, Asheville, NC October 1999

Invited speaker. District V meeting of the American College of Obstetricians and Gynecologists, Lexington, KY, October 1999

Invited speaker, XXVI International Symposium on Gynecological Oncology 99, Barcelona, Spain, December 1999

Invited speaker, 25th annual meeting. David A. Boyes Society, Vancouver Cancer Center, December 1999

Invited speaker, Baylor Medical Alumni Association, Houston, April 2000

Invited speaker, Amsterdam Menopause Symposium, April 2000

Participant: Stop the Increasing Morbidity of Breast Cancer Symposium, Amsterdam, April 2000.

Participant, Postgraduate course (moderator, presenter Symposium on Breast Cancer) American College of Obstetricians and Gynecologists annual meeting, San Francisco, May 2000

Invited speaker, 2nd International Conference on Ovarian Cancer, New York City, NY, June 2000

Invited speaker, Buffalo Ob/Gyn Society, 2000

Invited speaker, FIGO, Washington, DC, 2000

Invited speaker, NYU, New York City, 2000

Faculty member, American Society for Reproductive Medicine, NYU, 2000

Invited faculty member, New England Ob/Gyn Society, 2000

Frank R. Loche Professor and Lecturer, Wake Forest School of Medicine, 2000

Invited speaker, ACOG District IV, Asheville, NC, 2000

Invited speaker, Sunshine seminar, San Juan, PR, 2001

George Wilbanks Visiting Professor, University of South Florida School of Medicine, 2001

Invited speaker, Simposia Medico, San Juan, PR, 2001

Invited speaker, International Symposium on endometrial Cancer, Santiago, Chile, 2001

Participant, Management of Cytologic Abnormalities and Cervical Cancer Precursors NIH, 2001

Marvin Camel Lectureship, Washington University School of Medicine, 2001

Invited speaker, Novak Symposium, Maryland Ob/Gyn Society, 2001

Invited speaker, Controversies in Management of Gyn Malignancies, New York, NY, 2001

James W. Wiggins, M.D. Lectureship, Albuquerque, NM, 2001

Invited speaker, 10th World Congress on the Menopause, Berlin, 2002

Invited speaker, IX Portuguese Congress of Gynecology, Portugal, 2002

Invited lecture, European Gynecologic Oncology Society, Brussels, Belgium, 2003

Visiting Professor, North Shore University Hospital, NY, 2003

Invited lecturer, Masters in Gynecology, Emory University, 2003

Presidential speaker, North Carolina Obstetrical Gynecologic Society, Asheville, NC 2003

Invited speaker, Erlanger Cancer Symposium, Chattanooga, Tennessee, 2003

Invited speaker, Festival of Flowers Medical Symposium, Greenville, SC, 2003

Invited speaker, Annual Review Course, UCI, California, 2003

Invited speaker, Philip DiSaia Symposium, UCI, California, 2003

Invited lecturer, International Gynecological Cancer, Seoul, Korea, 2003

Richard TeLinde Lecturer, Johns Hopkins College of Medicine, Baltimore, MD, 2003

Invited speaker, Changing Perspectives, College of Health Sciences, Memphis, TN, 2003

Invited speaker, Update on Hormone Therapy: Why Such Controversy?, Hartford Hospital, University of Connecticut, Hartford, CT, 2003

Robert Wood Johnson Foundation award for excellence in end-of-life care textbook content for **Clinical Gynecologic Oncology**, 6th Edition., 2003

Endowment Fund Lectureship at the annual meeting of the South Atlantic Association of Obstetricians and Gynecologists, January 28-February 1, 2005, Orlando, Florida

Visiting Professor: Brigham and Women's Hospital, Boston, 2005

Keynote Speaker: X Congress of Gynecologists, Portugal, 2005

Keynote Speaker: Second Obstetrics and Gynecology Convention, Ponce, Puerto Rico, 2005
Keynote Speaker: Annual Gynecologic Oncology Symposium, University of Illinois Medical Center, 2005
Invited participant Ovarian Cancer State of Science Meeting, NIH, Washington, DC 2005
Visiting Professor: Mercer School of Medicine, Macon, Georgia, 2005
Program Director, Post graduate session, South Atlantic Association of Obstetricians and Gynecologists, Sulfur Springs, West Virginia, 2006
Grand rounds: Department of Obstetrics and Gynecology, Brigham & Women's Hospital, Boston, MA, 2005
Invited Speaker: Portuguese Congress of Gynecology Estrogen and Cancer Management Endometrial Cancer, Estoril, Portugal, 2006
Key Note Speaker: Annual Gynecologic Oncology Symposium. University of Illinois Medical Center, Chicago, IL
Guest Speaker: Second Obstetrics and Gynecology Convention Endometrial Neoplasia, Prevention, GU injuries: "Has the WHI Changed Your Practice", Ponce, PR, 2005
Presenter: Panel Meeting American Society for Reproductive Medicine, Estrogens and Cancer, Birmingham, AL, 2005
Invited Speaker, Gynecologic Oncology Group, "35 years of Excellence in Clinical Research", San Diego, CA.
South Atlantic Association Obstetricians and Gynecologists Endowment Fund Lectureship: What Goes Around Comes Around", Orlando, FL, 2006

Academic Reviews
and Committees:

Examiner, American Board of Obstetrics and Gynecology,

Examiner, American Board of Obstetrics and Gynecology,
Subspecialty Board, Gynecologic Oncology

Editorial Board:

Gynecologic Oncology
Obstetrics/Gynecology Report
Video Journal of Obstetrics and Gynecology
Journal of Clinical Medicine

International Correspondence Society of
Obstetricians and Gynecologists
International Journal of Gynecological Cancer
Annual Report on the Results of Treatment in
Gynecologic Cancers
Current Women's Health Reports
Preventive Medicine

Reviewer:

Cancer
American Journal of Obstetrics and Gynecology
Obstetrics and Gynecology
Southern Medical Journal
International Correspondence Society of Obstetricians
and Gynecologists
Cancer Clinical Trials
Gynecologic Oncology
European Journal of Obstetrics, Gynecology and
Reproductive Biology
New England Journal of Medicine
International Journal of Gynecologic Oncology
JAMA

Executive Committee, N. C. Cancer Hospital

Uterine Task Force - N. C. Chapter, American Cancer
Society

Hospital Affiliations:

Medical University of South Carolina
Charleston Memorial Hospital
Ralph H. Johnson Veterans Administration Hospital

Hospital/University
Committees:

Hospital Executive Committee
Hollings Oncology Center Steering Committee
MUSC Medical Center Operations Committee
Hospital Cancer Committee - Chairman
Search Committee, Chairman for Dermatology, Chairman
Search Committee, Chairman for Radiation Oncology,

Chairman

University Medical Associates Executive Committee
Hospital Operations Committee
Clinical Care Subcommittee
Operating Room Committee

D&T Steering Committee
Ambulatory Steering Committee
Search Committee, Director, Hollings Cancer Center

BIBLIOGRAPHY

1. Creasman, WT, Duggan, ER and Lund, CJ: Absorption of transfused chromium-labeled erythrocytes from the fetal peritoneal cavity in hydrops fetalis. *Amer J Obstet. & Gynecol.* 94:586-588, 1966.
2. Thiede, HA, Creasman, WT, and Metcalfe, S: Antenatal analysis of the human chromosomes. *Amer J Obstet. & Gynecol.* 94:589-590, 1966.
3. Creasman, WT: Back and hip pain in pregnancy due to chordoma. *Amer J Obstet. & Gynecol.* 99:1165-1166, 1967.
4. Creasman, WT, Lawrence, RA, and Thiede, HA: Fetal hazards in amniocentesis. *JAMA* 204:949-952, 1968.
5. Creasman, WT: Carcinoma of the cervix and the pregnant woman. *The Cancer Bulletin*, 22:25-26, 1970.
6. Creasman, WT, Rutledge, FN, and Fletcher, GN: Carcinoma of the cervix associated with pregnancy. *Obstet. & Gynecol.* 36:495-501, 1970.
7. Creasman, WT, Rutledge, FN, and Smith, JP: Carcinoma of the ovary associated with pregnancy. *Obstet. & Gynecol.* 38:111-116, 1971.
8. Creasman, WT and Rutledge, FN: Prognostic value of peritoneal cytology in gynecological malignant disease. *Amer. J. Obstet. & Gynecol.* 110:773-781, 1971. (Prize Thesis - South Atlantic Association of Obstetricians and Gynecologists).
9. Creasman, WT: Management of premalignant disease of the cervix. *Rocky Mountain Med. J.* 68(8):27-30, 1971.
10. Creasman, WT and Lukeman, J: The role of the fallopian tube in dissemination of malignant cells in corpus cancer. *Cancer* 29:456-457, 1972.
11. Henderson, SR, Lund, CJ and Creasman, WT: Antepartum pulmonary embolism. *Amer. J. Obstet. & Gynecol.* 112:476-478, 1972.
12. Creasman, WT and Rutledge, FN: Carcinoma in situ of the cervix: Analysis of 861 patients. *Obstet. & Gynecol.* 39:373-380, 1972.
13. Creasman, WT and Lukeman, J: Urinary cytology in gynecological malignancies. *Cancer* 30:148-149, 1972.
14. Creasman, WT: Preinvasive disease of the cervix: *Southern Medicine* 60(2):7-8, 1972.

15. Weed, JC Jr., Curry, SL and Creasman, WT: The non-surgical management of preinvasive disease of the cervix. *Southern Medicine* 60(2):25-31, 1972.
16. Curry, SL, Weed, JC Jr., and Creasman, WT: Pyometra: A complication of cryosurgery. *Obstet. & Gynecol.* 49:499-501, 1972.
17. Creasman, WT and Rutledge, F: Preoperative evaluation of patients with recurrent carcinoma of the cervix. *Gynecol. Oncol.* 1:111-118, 1972.
18. Hammond, CB, Borchert, L., Tyrey, L, Creasman, WT, and Parker, RT: Treatment of metastatic trophoblastic disease: Good and poor prognosis. *Amer. J. Obstet. & Gynecol.* 115:451-457, 1973.
19. Creasman, WT, Weed, JC Jr., Curry, SL, Johnston, WW and Parker, RT: The efficacy of cryosurgery in severe cervical intraepithelial neoplasia. *Obstet. & Gynecol.* 41:501-506, 1973. (President's Award, American College of Obstetricians and Gynecologists, 1973).
20. Creasman, WT and Parker, RT: Microinvasive carcinoma of the cervix: *Clin. Obstet. & Gynecol.* 16:261-275, 1973.
21. Wilbanks, GD, Creasman, WT, Kaufmann, LA and Parker, RT: The treatment of cervical dysplasia with electrocautery and tetracycline suppositories. *Amer. J. Obstet. & Gynecol.* 117:460-464, 1973.
22. Creasman, WT: Herpes virus II and its relationship to the progression of cervical intraepithelial neoplasia. *Cancer Research (Abstract)* 33:1512, 1973.
23. Morrow, CP, Creasman, WT, DiSaia, PJ, Curry, SL and DePetrillo, AD: Methotrexate, hydroxyurea, and vincristine: combined chemotherapy in squamous carcinoma of the female genitalia. *Gynecol. Oncol.* 1:314-319, 1973.
24. Creasman, WT: Does cryosurgery affect fertility? *Contemp. OB-GYN*, 4:81-85, 1974.
25. Creasman, WT and Rutledge, FN: Is positive pelvic lymphadenopathy a contraindication to radical surgery in recurrent cervical carcinoma? *Gynecol. Oncol.* 2:482-485, 1974.
26. Curry, SL, Hammond, CB, Tyrey, L, Creasman, WT and Parker, RT: Hydatidiform mole diagnosis, management and long-term follow-up of 347 patients. *Obstet. & Gynecol.* 45:1-8, 1975.
27. Townsend, DE, Brooks, PG, Creasman, WT, Crisp, WE and Richart, RM: Symposium on cryosurgery techniques: *Contemp. OB-GYN* 5:107-145, 1975.

28. Creasman, WT, Gallager, HS and Rutledge, F: Paget's disease of the vulva. *Gynecol. Oncol.* 3:133-148, 1975.
29. Creasman, WT and Parker, RT: Management of early cervical neoplasia. *Clin. Obstet. & Gynecol.* 18:233-246, 1975.
30. Weed, JC, Jr and Creasman, WT: meningeal carcinomatosis secondary to advanced squamous cell carcinoma of the cervix. *Gynecol. Oncol.* 3:201-205, 1975.
31. Parker, RT, Duncan, I, Rampone, J and Creasman, WT: Operative management of early invasive epidermoid carcinoma of the vulva. *Amer. J. Obstet. & Gynecol.* 123:349-355, 1975.
32. Creasman, WT, Rock, JA, Christakos, AC and Parker, RT: Genital cytological abnormalities in patients having therapeutic abortions. *Souther Med. J.* 69:199-200, 1976.
33. Gallager, HS, Creasman, WT and MacKoy, B: Paget's disease of the vulva, neoplasms of skin and malignant melanoma. *Year Book of Medical Publishers, Inc.*, pp 231-242, 1976.
34. Creasman, WT and Weed, JC Jr.: Screening techniques in endometrial cancer. *Cancer* 38:436-440, 1976.
35. Creasman, WT, Boronow, RC, Morrow, CP, DiSaia, PJ and Blessing, J: Adenocarcinoma of the endometrium: its metastatic lymph node potential. *Gynecol. Oncol.* 4:239-243, 1976.
36. Creasman, WT: The adnexal mass: its diagnosis and management. *Contemp. OB-GYN* 9:45-50, 1977.
37. Creasman, WT: Surgical management of adenocarcinoma of the endometrium (An original article). *OB-GYN Digest*, 11-16, 1977.
38. Creasman, WT: Some current concepts in the management of ovarian carcinoma. *NC Med J* 38:203-205, 1977.
39. Schmidt, HJ and Creasman, WT: Ovarian tumors. Current Diagnosis, Conn & Conn, pp. 1049-1053, W. B. Saunders Co., Philadelphia, PA, 1977.
40. McCarty, KS, Barton, TK, Peete, CH and Creasman, WT: Gonadal dysgenesis with adenocarcinoma of the endometrium. An electron microscopic and steroid receptor analysis with a review of the literature. *Cancer* 42:512-520, 1978.

41. Gall, SA, DiSaia, PJ, Schmidt, HJ, Mittelstaedt, L, Newman, P and Creasman, WT: Toxicity manifestations following intravenous corynebacterium parvum administration in patients with ovarian and cervical carcinoma. *Amer. J. Obstet. & Gynecol.* 132:555-560, 1978.
42. Omura, GA, Shingleton, HM, Creasman, WT, Blessing, JA and Boronow, R: Chemotherapy of gynecologic cancer with nitrosourea: A randomized trial of CCNU and Methyl CCNU in cancer of the cervix, corpus, vagina and vulva. *Cancer Treat. Reports* 62:833-835, 1978.
43. DiSaia, PJ, Morrow, CP, Boronow, RC, Creasman, WT and Mittelstaedt, L.: Endometrial sarcoma: lymphatic spread pattern. *Amer. J. Obstet. & Gynecol.* 130:104-105, 1978.
44. Weed, JC Jr., Curry, SL, Duncan, ID, Parker, RT and Creasman, WT: Fertility after cryosurgery of the cervix. *Obstet. & Gynecol.* 52:245-246, 1978.
45. Creasman, WT, Abu-Ghazaleh, S and Schmidt, HJ: Retroperitoneal metastatic spread of ovarian cancer. *Gynecol. Oncol.* 6:447-450, 1978.
46. Creasman, WT, Fetter, B, Hammond, CB and Parker, RT: Germ cell malignancies of the ovary. *Obstet. & Gynecol.* 53:226-230, 1979.
47. Hammond, CB, Jelovsek, FR, Lee, KL, Creasman, WT and Parker, RT: Effects of long-term estrogen replacement therapy, I. Metabolic effects. *Amer. J. Obstet. & Gynecol.* 133:525-536, 1979.
48. Hammond, CB, Jelovsek, FR, Lee, KL, Creasman, WT, and Parker, RT: Effects of long-term estrogen replacement therapy, II, Neoplasia. *Amer. J. Obstet. & Gynecol.* 133:537-547, 1979.
49. DiSaia, PJ, Creasman, WT and Rich, W: An alternate approach to early cancer of the vulva. *Amer. J. Obstet. & Gynecol.* 133:825-832, 1979.
50. Creasman, WT, Gall, SA, Blessing, JA, Schmidt, HJ, Abu-Ghazaleh, S, Whisnant, JK and DiSaia, PJ: Chemoimmunotherapy in the management of primary stage III ovarian cancer: A Gynecologic Oncology Group Study. *Cancer Treat. Rep.* 63:319-323, 1979.
51. Surwit, EA, Fowler, WC, Rogoff, EE, Jelovsek, F, Parker, RT, and Creasman, WT: Stage II carcinoma of the endometrium. *Int. J. Radiation Oncol.* 5:323-326, 1979.
52. Abu-Ghazaleh, S and Creasman, WT: unusual metastasis in carcinoma of the cervix uteri. *Surg. Gynecol. & Obstet.* 148:728-730, 1979.

53. Richart, RM, Averette, HE, Creasman, WT and Townsend, DE: Should CIN be treated cyrosurgically? *Contemp. Ob-Gyn* 14, 1979.
54. McCarty, KS Jr., Barton, TK, Fetter, B, Creasman, WT and McCarty, KS, Sr.: Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. *Amer. J. Path.* Vol. 96, No. 1, 1979.
55. Haney, AF, Hammond, CB, Soules, MR and Creasman, WT: Diethylstilbestrol-induced upper genital tract abnormalities. *Fertil. & Steril.* 31(2):142-146, 1979.
56. Sall, S, DiSaia, PJ, Morrow, CP, Mortel, R, Prem, K, Thigpen, JT and Creasman, WT: A comparison of medroxyprogesterone serum concentration by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. *Amer. J. Obstet. & Gynecol.* 135(5):647-650, 1979.
57. Creasman, WT and Weed, JC Jr.: Microinvasive cancer 1vs. occult cancer. *Int. J. Radiation Oncol. Biol. Phys.* 5:1871-1872, 1979.
58. Slayton, R, Creasman, WT, Petty, W, Bundy, B and Blessing, J: A phase II trial of VP-16 in the treatment of advanced squamous cell carcinoma of cervix and adenocarcinoma of the ovary. *Cancer Treatment Reports* 63:(11-12), 2089-2094, 1979.
59. Slayton R, Creasman WT and Bundy B: Phase II Trial of VP-16 in treatment of advanced squamous cell carcinoma of the cervix, ASCO, C-305, 1979.
60. Creasman, WT and Weed, JC Jr: Conservative management of cervical intraepithelial neoplasia. *Clin. Obstet. & Gynecol.* 22:281, 1980.
61. Harris, , Bagne, F, Sullivan, DC, Currie, JL and Creasman, WT: Properties of chromic phosphate P-32 Radiocolloid as a therapeutic agent. *Inv. Radiol.* 15(5):377, 1980.
62. Creasman, WT, McCarty, KS, Sr, Barton, TK and McCarty, KS Jr: Clinical correlates of estrogen and progesterone binding proteins in human endometrial adenocarcinoma. *Obstet. & Gynecol.* 55:363-370, 1980. (First Prize Paper, American College of Obstetricians and Gynecologists, 1980).
63. LaGasse, LD, Creasman, WT, Shingleton, HM, Ford, JH and Blessing, J: Results and complications of operative staging in cervical cancer. *Gynecol. Oncol.* 9:90-98, 1980.
64. Creasman, WT: Surgical treatment of endometrial carcinoma. *Gynecol. & Obstet.* 4:1-5, 1980.

65. Creasman, WT: Neoplasias of the cervix. Current Therapy in Obstetrics and Gynecology, Edition I, pp. 138-141, E. J. Quilligan, M. D., Editor, W. B. Saunders Company, 1980.
66. Creasman, WT and Weed, JC Jr: Cancer of the endometrium. Current Problems in Cancer, 5:3-33, 1980.
67. Hreshchyshyn, MM, Park, RC, Blessing, JA, Norris, HJ, Levy, D, LaGasse, LD and Creasman, WT: The role of adjuvant therapy in stage I ovarian cancer. *Amer. J Obstet. & Gynecol.* 138:139-145, 1980.
68. Jelovsek, FR, Hammond, CB, Woodard, BH, Draffin, R, Lee, KL, Creasman, WT Parker, RT: Risk of exogenous estrogen therapy and endometrial cancer. *Amer. J. Obstet. & Gynecol.* 137(1):85-91, 1980.
69. Sullivan, DA, Harris, C, Wilkinson, RW, Currie, JL, Creasman, WT: Bremsstrahlung imaging after intraperitoneal instillation of radioactive chromic phosphate, *J Nucl Med* 21:33, 1980.
70. Creasman, WT and Weed, JC Jr.: Complication of radiation hysterectomy. Complications in Obstetric and Gynecologic Surgery, pp.389-398, Schaefer, G. and Graber, E. A., Editors. Harper and Row Publishers, 1981.
71. Clarke-Pearson, DL and Creasman, WT: Diagnosis of deep venous thrombosis in obstetrics and gynecology by impedance phlebography. *Obstet. & Gynecol.* 58:52-57, 1981.
72. Lewis, JL Jr. , Creasman, WT, Franklin, EW III, and Masterson, BJ: Symposium: Avoiding, detecting and repairing fistulas. *Contemp. OB-GYN* 17:198-206, 1981.
73. Creasman, WT, Clarke-Pearson, DL, Ashe, C and Weed JC Jr.: The abnormal Pap smear--what to do next? *Cancer* 48:515-522, 1981.
74. Currie, JL, Bagne, R, Harris, C, Sullivan DL, Surwit, EA, Wilkinson, RH and Creasman, WT: Radioactive chromic phosphate suspension: Studies on distribution dose absorption and effective therapeutic radiation in phantoms, dogs, and patients. *Gynecol. Oncol.* 12:193-218, 1981. (First Prize Paper, Society of Gynecologic Oncologists, 1981).
75. Gall, SA, Creasman, WT, DiSaia, P, Bundy, B and Thigpen, J.: A randomized comparison of melphalan versus melphalan plus corynebacterium parvum in the treatment of stage III (optimal) epithelial carcinoma of the ovary. A preliminary Gynecologic Oncology Group Report. *Amer. J. Reprod.* 1(5):273-274, 1981.
76. Bagne, F, Currie, JL and Creasman, WT: Dose analysis of intraperitoneally administered chromic phosphate, P-32. *Med. Physiol.* 8(4):571, 1981.

77. Weed, JC Jr. and Creasman, WT: Pelvic exenterations: who is a candidate? *Gynecol. Oncol.* Controversies in Cancer Treatment. S. C. Ballon, Editor, pp. 185-193, G.K. Hall Publishers, Boston, 1981.
78. Creasman, WT, Clarke-Pearson, DL and Weed, JC Jr.: Results of outpatient therapy of cervical intraepithelial neoplasia. *Gynecol. Oncol.* 12:S306-316, 1981.
79. Judd, HL, Cleary, RE, Creasman, WT, Figge, DC, Kase, N, Rosenwaks, Z and Tagatz, GE: Estrogen replacement therapy. *Obstet. & Gynecol.* 58:267-275, 1981.
80. Szpak, G., Creasman, WT, Volmer, RT and Johnston, WW: Prognostic value of peritoneal cytology in endometrial cancer. *Acta Cytol.* 25:640-646, 1981.
81. Creasman, WT, Sasso, RA, Weed, JC Jr., Woodard, BH and McCarty, KS Jr.: Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. *Gynecol. Oncol.* 12:319-327, 1981.
82. Creasman, WT and Weed, JC Jr.: Carcinoma of the endometrium: clinical features and management. *Gynecologic Oncology Fundamental Principles and Clinical Practice* 2:562-577, Editor, M. Coppleson, Churchill Livingstone, Edinburgh, 1981.
83. Creasman, WT, DiSaia, PJ, Blessing, J, Wilkinson, RH, Johnston, W and Weed, JC Jr.: Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. *Amer. J. Obstet. & Gynecol.* 141:(8):921-929, 1981.
84. Sasso, RA, Woodard, BH, McCarty, KS Jr., McCarty, KS, and Creasman, WT: Carcinoma: histologic and clinical correlates of estrogen and progesterone receptors. *Lab. Invest.* 44:58A, 1981.
85. Creasman, WT, Hill, G, Weed, JC Jr. and Gall, SA: The efficacy of prophylactic cefamandole in "extended" gynecological surgery. *Obstet. & Gynecol.* 59:309-314 1982.
86. Creasman, WT, Park, R, Norris, H, DiSaia, PJ, Morrow, P, Hreshchyshyn, MM and Blessing, J: Stage I borderline ovarian tumors. *Obstet. & Gynecol.* 59:93-96, 1982.
87. Clarke-Pearson, DL, Synan, IS, and Creasman, WT: Significant venous thromboembolism caused by pelvic lymphocysts: diagnosis and management. *Gynecol. Oncol.* 13:136-143, 1982.

88. Clayton, LA, Gall, SA, Dawson, JR, and Creasman, WT: Immune complexes in ovarian cancer. *Gynecol. Oncol.* 13:203-212, 1982.
89. Gall, SA, Creasman, WT, Blessing, JA, Whisnant, JK, and DiSaia, PJ: Chemoimmunotherapy in primary stage III ovarian epithelial cancer. Immunotherapy of Human Cancer, Terry and Rosenberg, editors, Elsevier North Holland, Inc., pp.337-341, 1982.
90. Johnston, WW, Myers, B, Creasman, WT and Owens, SM: Cytopathology and the management of early invasive cancer of the uterine cervix. *Obstet. & Gynecol.* 60:350-353, 1982.
91. Creasman, WT, Fowler, WC and Homesley, HD: Screening for cervical cancer: 1982-an update. *N.C. Med. J.* 43:(11),771-773, 1982.
92. Creasman, WT and Weed, JC Jr.: Diagnosis and management of in-situ carcinoma, microinvasive carcinoma and stage I invasive carcinoma of the cervix. Reid's Controversy in Obstetrics and Gynecology-III. Zuppan and Christian, editors. W. B. Saunders Co., pp. 624-630, 1983.
93. Sullivan, DC, Harris, CC, Currie, JL, Wilkinson, RH and Creasman, WT: Observations on the intraperitoneal distribution of chromic phosphate (^{32}P) suspension for intraperitoneal therapy. *Radiology* 146:539, 541, February 1983.
94. Clarke-Pearson, DL, Jelovsek, FR and Creasman, WT: Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. *Obstet. & Gynecol.* 61:(1):87-94, 1983.
95. Creasman, WT and Clarke-Pearson, DL: Abnormal cervical cytology: spotting it, treating it. *Contemp. OB-GYN* 21:53-76, June 1983.
96. Thigpen, JT, Ehrlich, CE, Creasman, WT, Curry, S, and Blessing, JA: Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group Study. *Amer. J. Clin. Oncol. (CCT)* 6:273-275, 1983.
97. Omura, GA, Major, FJ, Blessing, JA, Sedlacek, TV, Thigpen, JT, Creasman, WT and Zaino, RJ: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. *Cancer* 52:626-632, August 1983.
98. Creasman, WT and Clarke-Pearson, DL: Ovarian carcinoma. Current Therapy in Obstetrics and Gynecology 2. Edward J. Quilligan, M. D., Editor, W. B. Saunders Co., pp. 198-200, 1983.

99. Creasman, WT and Clarke-Pearson, DL: Immunological therapy-monitoring". Cancer Campaign, Vol. 7, Carcinoma of the Ovary, p.213, Edited by H.G. Bender and L. Beck, Gustav-Fischer-Verlag, Stuttgart-New York, 1983.
100. Creasman, WT and Clarke-Pearson, DL: "Immunotherapy of ovarian cancer". Clinics in Obstetrics and Gynecology, 10:297, Editor, DiSaia, PJ, M.D., W.B. Saunders, London, 1983.
101. Currie, JL, Gall, SA, Weed, JC Jr and Creasman, WT: Intracavitary C. parvum for treatment of malignant effusions. Gynecol. Oncology 16:6-14, 1983.
102. Clarke-Pearson, DL, Creasman, WT, Ralston, M, and Coleman, RE: Detection of postoperative pelvic vein thrombi by autologous-indium labeled platelet imaging. Obstet. Gynecol. 62:109-116, 1983.
103. Figge, DC and Creasman, WT: Cryotherapy in the treatment of cervical intraepithelial neoplasia. Obstet. Gynecol. 62:353, 1983.
104. Clarke-Pearson, DL, Synan, IS, and Creasman, WT: Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Amer. J. Obstet. & Gynecol. 147:369-375, 1983.
105. Clarke-Pearson, DL, Coleman, RE, Synan, IS, Hinshaw, W and Creasman, WT: Venous thromboembolism prophylaxis in gynecologic oncology. A prospective controlled trial of low-dose heparin. Amer. J. Obstet. & Gynecol. 145:606-613, 1983.
106. Bandy, LC, Clarke-Pearson, DL and Creasman, WT: Vitamin B-12 deficiency following therapy in gyn oncology. Gynecol. Oncol. 17:370-374, 1984.
107. Creasman, WT, Hinshaw, WM and Clarke-Pearson, DL: Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet. Gynecol. 63:145-419, 1984.
108. Clarke-Pearson, DL, Synan, IS, Hinshaw, W, Coleman, RE, and Creasman, WT: Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet. & Gynecol. 63:92-98, 1984.
109. Creasman, WT and Clarke-Pearson, DL: Pelvic exenteration. Progress in obstetrics and gynecology, 4:243-253, John Studd, Editor. Churchill-Livingstone, London, 1984.
110. Morrow CP, Creasman WT, Homesley H, Wilbanks G and Bundy B: Recurrence in endometrial carcinoma as a function of extended surgical staging data. Gynecol Oncol 17:262, 1984.

111. Berman ML, DiSaia, PJ, Kemp H, Creasman WT, Blessing J and Bundy B: Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes. *Gynecol Oncol* 17:263, 1984.
112. Abu-Ghazaleh, S, Johnston, W and Creasman, WT: The significance of peritoneal cytology in patients with carcinoma of the cervix. *Gynecol. Oncol.* 17:139-148, 1984.
113. Muss, HB, Slavik, M, Bundy, B, Stehman, FB and Creasman, WT: A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. (A Gynecologic Oncology Group Study). *Amer. J. of Clin. Oncol.* 7:257-260, 1984.
114. Berman, ML, Keys, H, Creasman, WT, DiSaia, P, Bundy, B, and Blessing, J: Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (A Gynecology Oncology Group Study). *Gynecol. Oncol.* 19:8-16, 1984.
115. Creasman, WT, Smith, EB, and Clarke-Pearson, DL: "Gestational trophoblastic disease". The Female Patient. *Practical OB-GYN Medicine* 7:66-76, 1984.
116. Soper, JT, McCarty, KS Jr., Hinshaw, WM, Creasman, WT, McCarty, KS Sr. and Clarke-Pearson, DL: Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. *Amer. J. Obstet. & Gynecol.* 150:342-348, 1984.
117. Soper, JT, McCarty, KS Jr., Creasman, WT, Clarke-Pearson, DL and McCarty, KS Sr.: Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. *Amer. J. Obstet. & Gynecol.* 150:437-439, 1984.
118. Clarke-Pearson, DL, Synan, IS, Coleman, RE, Hinshaw, W, and Creasman, WT: The natural history of venous thromboemboli in gynecologic oncology: A prospective study of 382 patients. *Amer. J. Obstet. & Gynecol.* 148:1051, 1984.
119. Clarke-Pearson, DL, Creasman, WT, Coleman, RE, Synan, IS and Hinshaw, WM: Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. *Gynecol. Oncol.* 18:226-232, 1984.
120. Slavik, M, Petty, WM, Blessing, JA, Creasman, WT and Homesley, HD: Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma. (A Gynecologic Oncology Group Study). *Cancer Treatment Reports.* 68:809, 1984.
121. Slavik, M, Petty, WM, Blessing, JA, Creasman, WT and Homesley, HD: Phase II clinical study of tamoxifen in advanced and recurrent endometrial adenocarcinoma. *ASCO* 3:C-666, 1984.

122. Clarke-Pearson, DL, Coleman, RE, Petry, N, Synan, IS, and Creasman, WT: Postoperative pelvic vein thrombosis and pulmonary embolism detected by indium III-labeled platelet imaging. A case report. *Amer J Obstet. & Gynecol.* 149:796-798, 1984.
123. Creasman, WT and Clarke-Pearson, DL: "Ovarian cancer: postoperative management." *Contemporary Issues in Clinical Oncology. Gynecologic Cancer.* Editor: A. A. Forastiere, Churchill-Livingstone, Inc., New York, 1984.
124. Boronow, RC, Morrow, CP, Creasman, WT, DiSaia, PJ, Silverberg, SG, Miller, A and Blessing, JA: Surgical staging in endometrial cancer: I. Clinical-pathologic findings of a prospective study. *Obstet. & Gynecol.* 63:825-832, 1984.
125. Smith, EB, Clarke-Pearson, DL, and Creasman, WT: A VP-16-213 and CIS platinum containing regimen for treatment of refractory ovarian germ cell malignancies. *Amer. J. Obstet. & Gynecol.* 150:927-931, 1984.
126. Clarke-Pearson, DL, DeLong, ER, Synan, IS and Creasman, WT: Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. *Obstet. & Gynecol.* 64:689-694, 1984.
127. DiSaia, PJ, Creasman, WT, Boronow, RC and Blessing, JA: Risk factors and recurrent patterns in stage I endometrial carcinoma. *Am. J. Obstet. & Gynecol.* 151(8):1009-1015, 1984.
128. Holcomb G, Creasman WT, Barker S et al: Peritoneal washings in patients with mixed mullerian tumors of the uterus, *Acta Cytol* 28:632-655, 1984.
129. Abdulhay G, DiSaia P, Creasman W, Homesley H, Whisant J: Human lymphoblastic interferon (HLgIFN) in the treatment of advanced epithelial ovarian malignancies. *ASCO* 3:167, 1984.
130. Bandy, LC, Clarke-Pearson, DL, Silverman, PM and Creasman, WT: Computed tomography in evaluation of extrapelvic lymphadenopathy in carcinoma of the cervix. *Obstet. & Gynecol.* 64:73, 1985.
131. Smith, EB, Clarke-Pearson, DL and Creasman, WT: "Screening for cervical cancer". Screening and Monitoring of Cancer, Vol. 4, John Wiley and Sons Limited Publisher. Basil Stoll, M. D., Editor, 1985.
132. Fortier, KJ, Clarke-Pearson, DL, Creasman, WT, and Johnston, WW: Fine needle aspiration in gynecology: Evaluation of extrapelvic lesions in patients with gynecologic malignancy. *Obstet. & Gynecol.* 65:67, 1985.

133. Creasman, WT and Bandy, LC: "Surgical management of ovarian cancer." *Surgical Rounds* 8:120-133, 1985.
134. Creasman, WT, Soper, JT, McCarty, KS Jr., McCarty, KS Sr., Hinshaw, W, Clarke-Pearson, DL: Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. *Am. J. Obstet. & Gynecol.* 151:922-932, 1985.
135. Barter, JF, Smith, EB, Szpak, CA, Hinshaw, MS, Clarke-Pearson, DL, and Creasman, WT: Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases. *Gynecol. Oncol.* 21:220-227, 1985.
136. Muss, HB, Bundy, B, DiSaia, PJ, Homesley, HD, Fowler, WC Jr., Creasman, WT and Jordan, E: Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (A phase III trial of the Gynecology Oncology Group). *Cancer* 55:1648-1653, 1985.
137. Slayton, RE, Park, RC, Silverberg, SG, Shingleton, H, Creasman, WT and Blessing, JA: Vincristine, Dactinomycin and Cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. (A Gynecologic Oncology Group Study- A final report). *Cancer* 56:243-248, 1985.
138. Abdulhay, G, DiSaia, PJ, Blessing, JA and Creasman, WT: Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies. A Gynecologic Oncology Group Study. *Amer. J. Obstet. & Gynecol.* 152:418-423, 1985.
139. Creasman, WT, Fetter, BF, Clarke-Pearson, DL, Kaufmann, L and Parker, RT: Management of stage I-A carcinoma of the cervix. *Amer. J. Obstet. & Gynecol.* 153 (2) 164-172, September 1985.
140. Cox, EB, Budwit, DA, Miller, L, Clarke-Pearson, D, McCarty, KS Sr., McCarty, KS Jr. and Creasman, WT: Use of monoclonal antibodies for immunohistochemical estrogen receptor analyses in endometrial adenocarcinoma. ASCO Meeting. Houston, Tx May 1985
141. Soper, JT, Creasman, WT, Clarke-Pearson, DL, Sullivan, DC, Vergadoro, F, Johnston, WT: Intraperitoneal chromic phosphate P-32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. *Amer. J. Obstet. & Gynecol.* 153 (2) 191-196, September 1985.
142. Creasman, WT: Symposium on cervical neoplasia II. Cryosurgery. *Colposcopy and Gynecologic Laser Surgery* 1:(4)275-279, 1984/85.
143. Morrow CP, Creasman WT, Homesley H, Yordan E, Park R and Bundy B: Recurrences in endometrial carcinoma as a function of extended surgical

- stagings In: *Gynecologic Oncology*, Morrow Cp and Smart GE (eds) Springer-Verlag NY 147, 1985.
144. Reid, R, Atkinson, K, Chanen, W, Coppleson, M, Creasman, W and Jordan, J: Symposium on cervical neoplasia VI. Differing Views. 1:(4) 299-306, 1984/85.
 145. Soper, JT, McCarty, KS Jr., Creasman, WT and McCarty, KS Sr.: Histologic control of biochemical steroid receptor analysis in endometrial carcinomas. *Amer. J. Obstet. & Gynecol.* 153 (5)520-523, 1985.
 146. Creasman, WT and Soper, JT: Assessment of the contemporary management of germ cell malignancies of the ovary. *Amer. J. Obstet. & Gynecol.* 153(8) 828-834, 1985.
 147. Clarke-Pearson, DL, Creasman, WT: "A clinical evaluation of absorbable polydioxanone ligating clips in abdominal and pelvic surgery". *Surg. Gynecol. & Obstet.* 161:250-252, 1985.
 148. Soper, J, Cox, E, Creasman, W, McCarty, KS Sr., McCarty, KS Jr.: Immunohistologic localization of estrogen receptor using monoclonal (H222 Sp)Antibody in endometrial carcinoma (abstract). *Gynecol. Oncol.* 20:256, 1985.
 149. Smith EB and Creasman WT: Preinvasive and invasive cervical neoplasia in pregnancy: Principles of Medical therapy in Pregnancy. Appleton and Lange, East Norwalk, CT, 1985.
 150. Puleo, JG, Clarke-Pearson, DL, Smith, EB, Barnard, D and Creasman, WT: Superior vena cava syndrome associated with gynecologic malignancy. *Gynecol. Oncol.* 23(1) 59-64, 1986.
 151. Creasman, WT, Henderson, D, Hinshaw, W and Clarke-Pearson, DL: Estrogen replacement therapy in the patient treated for endometrial cancer. *Obstet. & Gynecol.* 67: (3) 326-330, 1986.
 152. Clarke-Pearson, DL and Creasman, WT: Ovarian carcinoma. "Comprehensive Textbook of Oncology." Williams and Wilkins. Moossa, AR, Robson, MC, and Schimpff, SC, editors. 845-854, 1986.
 153. Thigpen, JT, Blessing, JA, Homesley, HD, Berek, JS and Creasman, WT: Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: A Gynecologic Oncology Group Study. *Gynecol. Oncol.* 23(1) 101-104, 1986.
 154. Omura, G, Blessing, JA, Ehrlich, CE, Miller, A, Yordan, E, Creasman, WT and Homesley, HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Gynecology Oncology Group Study. *Cancer* 57:1725, 1986.

155. Morrow, CP, Creasman, WT, Homesley, H, Yordan, E, Park, R and Bundy, B: Recurrence in endometrial carcinoma as a function of extended surgical staging date. *Gynecological Oncology*. Morrow, CP and Smart, GE, editors. Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1986.
156. Creasman, WT and Soper, JT: The undiagnosed adnexal mass after the menopause. *Clin. Obstet. & Gynecol.* 29(2) 446-452, June 1986.
157. Soper, JT and Creasman, WT: Vulvar dystrophies. *Clin. Obstet. & Gynecol.* 29(2)431-439, June 1986.
158. Geszler, G, Szpak, CA, Harris, RE, Creasman, WT, Barter, JF and Johnston, WW: Prognostic value of peritoneal washings in patients with malignant mixed mullerian tumors of the uterus. *Amer. J. Obstet. & Gynecol.* 155(1)83-89, July 1986.
159. McCarty, KS Jr., McCarty, KS Sr, Cox, EB, Leight, GS, Miller, L, Konrath, J, Flowers, JL, Soper, JT, Szabo, E, Budwit, DA, Creasman, WT and Seigler, HF: Use of monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. *Cancer Research (Suppl)* 46:4244s-4248s, August 1986.
160. Clarke-Pearson, DL, Bandy, LC, Dudzinski, M, Heaston, D and Creasman, WT: Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findings. *JAMA* 255(5):627-630, 1986.
161. Creasman, WT: Malignant lesions of the corpus uteri. Obstetrics and Gynecology, 5th Edition, Danforth, D and Scott, JR, Editors, pp.1068-1096, Lippincott Publishing Co., 1986.
162. DiSaia, PJ and Creasman, WT: Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy. *Clinics in Obstet. Gynecol.* 13(4):751-766, 1986.
163. Creasman, WT: ERT after surgery for endometrial ca? *Contemp. OB-GYN* 28(4):39-46, 1986.
164. Budwit-Novotny, DA, McCarty, KS, Cox, EB, Soper, JT, Mutch, DG, Creasman, WT, Flowers, JL, and McCarty, KS JR.: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. *Cancer Research* 46:5419-5425, October 1986.

165. Queenan, JT, Creasman, WT, Drukker, BH, Eskey, PN Jr., and Merkatz, IR: The periodic gyn exam: establishing continuity of care. *Contemp. OB-GYN*, 28(5):172-196, November 1986.
166. Creasman, WT, Soper, JT, and Clarke-Pearson, D: Radical hysterectomy as therapy for early carcinoma of the cervix. *Am J Obstet Gynecol*.155:964-969, 1986.
167. Creasman, WT, Soper, JT, McCarty KS Jr., and McCarty, KS Sr.: Influence of steroid receptor content on prognosis of early stage endometrial carcinoma. *Gynecology and Obstetrics*, edited by H. Ludwig and K. Thomsen, Springer-Verlag Berlin Heidelberg, p.482, 1986.
168. Creasman, WT: Prognostic factors and their therapeutic implications in endometrial carcinoma, *Gynecology and Obstetrics*, edited by h. Ludwig and K. Thomsen, Springer-Verlag, Berlin, Heidelberg, p. 484, 1986.
169. Budwit-Novotny, DA, McCarty, KS, Cox, EB, Soper, JT, Mutch, DG, Creasman, WT, Flowers, JL, McCarty, Jr. KS: Immunohistochemical analyses of ER in endometrial adenocarcinoma using a monoclonal antibody. *Cancer Research* 46:5419, 1986.
170. Mutch, DG, Budwit, DA, Cox EB, Soper, JT, Creasman, WT, McCarty, KS and McCarty, KS Jr.: Endometrial adenocarcinoma estrogen receptor content-associations of clinicopathologic features with immunohistochemical analysis compared with standard biochemical determination. *Gynecol Oncol*. 255, 1986.
171. Creasman, WT, Soper, JT: Endometrial carcinoma. *Current Therapy in Surgical Gynecology*, pp.200-203, 1987.
172. Clarke-Pearson, DL, Chin, NO, DeLong, ER, Rice, Reed, and Creasman, WT: Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, survival. *Gyn Oncol* 26:11-18, 1987.
173. Clarke-Pearson, DL, DeLong, ER, Synan, IS, Coleman, RE and Creasman, WT: Variables associated with postoperative deep venous thrombosis: A prospective study of 411 gynecology patients and creation of a prognostic model. *Obstet Gynecol*. 69(2):146-150, February 1987.
174. Bearman, DM, MacMillan, JP and Creasman, WT: Papanicolaou smear history of patients developing cervical cancer: An assessment of screening protocols. *Obstet Gynecol*. 69(2):151-155, February 1987.
175. Bandy, LC, Clarke-Pearson, DL, Soper, JT, Mutch, DG, MacMillan, J. and Creasman, WT: Long-term effect on bladder function following radical hysterectomy with and without postoperative radiation. *Gyn Oncol* 26:160-168, Feb 1987.

176. Soper, JT, Wilkinson, RH, Bandy LC, Clarke-Pearson, DL and Creasman, WT: Intraperitoneal chronic phosphate P³² as salvage therapy for persistent carcinoma of the ovary after surgical restaging. *Am J Obstet Gynecol* 156:1153, 1987.
177. Major F, Silverberg S, Morrow P, Blessing J, Creasman W and Currie J. A preliminary analysis of prognostic factors in uterine sarcoma. *Gynecol. Oncol.* 26:411, 1987.
178. Soper, JT, Cox, EB, Budwit-Novotny, DA, Mutch, DG, Creasman, WT, McCarty, KS Sr, and McCarty, KS Jr.: Histologic composition of endometrial carcinoma analyzed for steroid receptor content. *Am. J. Obstet. Gynecol.* 157:26, July 1987.
179. Creasman, WT, Morrow, CP, Bundy, BN, Homesley, HD, Graham, JE and Heller, PB: Surgical pathologic spread patterns of endometrial cancer: A Gynecologic Oncology Group Study. *Cancer* 60:2035, 1987.
180. Jones, DED, Creasman, WT, Dombroski, RA et al: Evaluation of the atypical Pap smear. *Am. J. Obstet. Gynecol.* 157:544-9, 1987.
181. Mutch, David G., Soper, John T., Budwit-Novotny, Debra A., Cox, Edwin B., Creasman, W. T., McCarty, Sr., K. S. and McCarty, Jr., K. S.: Endometrial adenocarcinoma estrogen receptor content: Association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. *Am. J. Obstet. Gynecol.* 157:924, 1987.
182. Creasman, W. T.: Uterine leiomyomas with retroperitoneal lymph node involvement. *Southern Medical Journal* 80:1320, 1987.
183. Soper JT, Wilkinson R, Bundy L, Clarke-Pearson, DL and Creasman, WT: Intraperitoneal chronic phosphorous (P-32) as salvage therapy for persistent ovarian carcinoma. *Gyn Oncol* 26:411, 1987
184. Soper JT, Humnter V, Tanner M, Creasman WT, Bast RC Jr.: Use of CA 125, CA 72 and CA 15-3 to discriminate malignant from benign pelvic masses (abst.) *Proc. Am Assoc. Cancer Res.* 28:205, 1987.
185. Creasman, WT: Cooperative program endeavors in gynecologic oncology, *Attualita in Oncologia Ginecologica*, Massi GB, Scarselli G (Eds) Edizioni Riviste Scientifiche, Firenze, p. 20-29, 1987.
186. Curry S, Blessing J, DiSaia P, Creasman W and Twigg L: A prospective randomized comparison of MAC versus modified bagsharve regime in Poor Prognosis gestational trophoblastic disease. *Gynecol Oncol*, 1987.

187. Clarke-Pearson, DL, DeLong, ER, Chin, N., Rice, R and Creasman, WT: Intestinal obstruction in patients with ovarian cancer. Arch Surg 123:42, Jan. 1988.
188. Clarke-Pearson, DL, Soper, JT, and Creasman, WT: Absorbable synthetic mesh (polyglactin 910) for the formation of a pelvic "lid" after radical pelvic resection. Am J Obstet Gynecol 185:158, January 1988.
189. Soper, John T., Clarke-Pearson, Daniel L. and Creasman, William T.: Absorbable synthetic mesh (910 Polyglactin) intestinal sling to reduce radiation-induced small bowel injury in patients with pelvic malignancies. Gynecol Oncol 29:283-289, 1988.
190. Soper JT, Blaszczyk TM, Oke E, Clarke-Pearson D and Creasman WT: Percutaneous nephrostomy in gynecologic oncology patients, Am J Obstet Gynecol 158:1126, 1988.
191. Creasman, WT: Protocolli cooperativi in oncologia ginecologica. Rivista di Ostetricia Ginecologia, Vol. I, p. 5 1988.
192. Stehman, FB, Bundy, BN, Keys, H., Currie, JL, Mortel, R. and Creasman, WT: A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. Am J Obstet. Gynecol.159:87,1988.
193. Beecham J, Blessing J, Creasman W, Hatch, K: tamoxifen responsiveness, hormone receptor and tumor grade: A prospective study of 105 advanced ovarian cancer patients. Gynecol Oncol 29:136, 1988.
194. Beecham J, Blessing J, Creasman W, Hatch, K: tamoxifen responsiveness, hormone receptor and tumor grade: A prospective study of 105 advanced ovarian cancer patients. ASCO 7:135, 1988.
195. McGuire WP, Arseneau JC, Blessing J, Given F, Hatch K, Creasman W, DiSaia P and Teng N: Randomized comparison of carboplatinum and iproplatin in advanced squamous carcinoma of uterine cervix, ASCO 7:521, 1988. J. Clin Oncol 7(10):1462,1989.
196. Creasman WT and Eddy GL: Prognostic factors in relationship to second-look laparotomy in ovarian cancer. Bailliere's Clinical Obstetrics and Gynecology 3(1), 183, 1989.
197. Creasman WT and Eddy GL: Critical analysis of prognostic factors of ovarian cancer. **Multimodal Treatment of Ovarian Cancer Editors Pier Franco Conte, Nicola Ragni, Riccardo Rosso, Jan B. Vermorken, Vol. 20, 1989.**

198. Thigpen JT, Blessing, JA, Homesley H, Creasman WT, Sutton G: Phase II trial of cisplatin s first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. *Gynecol Oncol* 33:68, April 1989.
199. Eddy GL and Creasman WT: Management of vulvar lesions: Unusual cases. *Obstetrics/Gynecology Report* 1(2):222,1989.
200. Eddy GL and Creasman WT: Treatment of condyloma acuminatum, *Obstetrics/Gynecology Report* 1(2):261, 1989.
201. Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT and McCarty KS: Endometrial Cancer: Histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. *Obstet. Gynecol.*73:780, 1989.
202. Casman WT: Premalignant lesions of the vulva. *Obstetrics and Gynecology Forum* 3:4, 1989.
203. Hunter V, Christensen C, Blazck T, Soper J, Creasman WT, Clarke-Pearson D. Surgical staging in advanced cervical cancer. *Gynecol Oncol* 32:113, 1989.
204. Creasman WT, Marchant DJ: Can a woman with a history of breast cancer be given postmenopausal estrogen replacement? *OB/GYN Forum*, Daniel R. Mishell, Jr., Ed. Vol 4(2):1, 1989.
205. Creasman WT: Presidential Address: One Score + 11 = 2000 Presented at the 20th Annual Meeting of the Society of Gynecologic Oncologists, Maui, Hawaii, February 8, 1989. *Gyn Oncol* 34:255, 1989.
206. Creasman WT: How good (or bad) is the Pap smear? *J SCMA* 85:459, October 1989.
207. Soper JT, Berchuck A, Creasman WT and Clarke-Pearson DP: Pelvic exenteration: factors associated with major surgical morbidity. *Gyn Oncol* 35:93-98, 1989.
208. Creasman WT and Eddy GL: Evaluation of the Adnexal Mass, *Gyn Oncology Consult*, December 1989.
209. Berman ML, Soper JT, Creasman WT, Olt GT, DiSaia, PJ: Conservative surgical management of superficially invasive stage I vulvar carcinoma. *Gyn Oncol* 35:352-357, 1989.
210. Delgado G, Bundy BN, Fowler WC, Stehman FB, Seven B, Creasman WT, Major F, DiSaia PJ and Zaino R: A prospective surgical pathological study of stage I squamous carcinoma of the cervix: A GOG study. *Gyn Oncol.* 35:314, 1989.

211. Creasman WT, Gall S, Bundy BN, Beecham J et al: Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (A GOG Study), *Gynecol Oncol* 35:378-382, 1989.
212. McGuire WP, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT, Teng NNH and Creasman WT: A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. *J Clin Oncol* 7:1462-1468, October 1989.
213. Creasman, WT: ACS guidelines for mammography: Guidelines should be reevaluated. *OB/GYN Report* 2(1):75, 1990.
214. Soper JT, Hunter VJ, Daly L, Tanner M, Creasman, WT, Bast, RC Jr.: Preoperative serum tumor-associated antigen levels in women with pelvic masses, *Obstet Gynecol* 75:249, 1990.
215. Creasman WT: Graduate Education: New Gynecologic Cancer Staging, *Obstet. Gynecol.* 75:287, 1990.
216. Morrow CP, Bundy, BN, Homesley HD, Creasman WT, Hornback NB, Kurman R and Thigpen, JT: Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, Stage I and Occult Stage II: A Gynecology Oncology Group Study, *Gyn Oncol.* 36:166, Feb. 1990.
217. Clarke-Pearson, DL, DeLong, E, Synan, IS, Soper JT, Creasman WT and Coleman RE: A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. *Obstet. Gynecol* 75:684, April 1990.
218. Soper JT, Segreti EM, Novotny DB, Mutch D, Creasman WT, and McCarty KS Jr.: Estrogen and progesterone receptor content of endometrial carcinomas: Comparison of total tissue versus cancer component analysis. *Gyn Oncol.* 36:363, March 1990.
219. Creasman WT and Eddy GL: Vulvar intraepithelial neoplasia: Definition and diagnosis. *Gyn Oncol. Consult* May 1990.
220. Soisson AP, Soper JT, Clarke-Pearson DP, Berchuck A, Montana G and Creasman WT: Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. *Gyn Oncol* 37:390, June 1990.
221. Eddy GL and Creasman WT: Choosing among topical agents, surgery and immunotherapy. *Obs Gynecol Report* 1:261, 1989.

222. Sutton G, Brian B, Delgado G, Sevin B, Creasman W, Major F, Zaino R: Ovarian Metastases in Stage IB cervical carcinoma. (Abstract) SGO, February 1990.
223. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT and Major F.: Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a GOG Group Study. *Gynecol Oncol* 38:352-357, 1990.
224. Creasman WT and Eddy GL: Recent advances in endometrial cancer. *Seminars in Surg Oncol* 6:339-42, 1990.
225. Creasman WT, Omura GA, Brady MF, Yordan E, DiSaia PJ, and Beecham J.: A randomized trial of cyclophosphamide, doxorubicin and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer. A GOG Study. *Gyn Oncol* 39:239-243, 1990.
226. Mutch DG, Soper JT, Babcock CJ, Creasman WT and Hammond CB: Recurrent gestational trophoblastic neoplasm (GTN): Experience of the Southeastern Regional Trophoblastic Disease Center (SRTDC): *Cancer* 1990; 66:978-982.
227. Hughes CL Jr., Wall LL, Creasman WT: Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. *Gyn Oncol* 40:42-45, January 1991.
228. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HH and Graham JE: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A GOG Study. *Gyn Oncol* 40:55-65, January 1991.
229. Creasman WT: Estrogen replacement therapy: Is previously treated cancer a contraindication? *Obstet. Gynecol* 77:308-312, February 1991.
230. Creasman WT and DiSaia PJ: Screening in ovarian cancer. *Am J. Obstet. Gynecol* 165:7-10, July 1991.
231. Bast, RC, Knife, S, Epenetos, A, Dhokia B. Creasman W et al. Coordinate evaluation of serum markers in ovarian cancer but not in benign disease. *Cancer* 68:1758, October 1991.
232. Montz FJ, Creasman WT, Eddy GL et al. Running mass closure of abdominal wounds using absorbable looped suture. *J of Gynecol Surg* 7:107, 1991.
233. Hatch K, Beechman J, Blessing JA, Creasman WT: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. *Cancer* 68:269-71, 1991

234. Massad LS, Hunter VJ, Szpak CA, Clarke-Pearson, DL, and Creasman WT: Epithelial ovarian tumors of low malignant potential. *Obstet Gynecol* 78:1027, December 1991.
235. Sutton GP, Bundy BN, Delgado G, Sevin BU, Creasman WT, Major FJ and Zaino R.: Ovarian metastases in stage IB carcinoma of the cervix: A Gynecologic Oncology Group study. *Amer J Obstet Gynecol* 166:50, January 1992.
236. Creasman WT: The Burke Article Reviewed. *Oncology* 1992 6:119.
237. Stehman FB, Bundy BN, Dvoretzky PM and Creasman WT: Early Stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: A prospective study of the GOG. *Obstet Gynecol* 79:491, April 1992.
238. Creasman, WT: Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer. *Oncology* 6:23, July 1992.
239. Creasman WT: Adenocarcinoma of uterine corpus. Submitted to "Current Science—Gynecologic Oncology Section, August 1992.
240. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E and Brady MF: Prognostic factors in early stage uterine sarcoma: A Gynecologic Oncology Group study, *Int J Gynecol Pathol* 11:75, 1992.
241. Stehman FB, Bundy BN, Thomas G, Keys HM, D'Ablaing G, Fowler WC, Mortrel R and Creasman WT: Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long term follow-up of a Gynecologic Oncology Group Trial, *J Clin Oncol* 11:1523-28, 1993
242. Creasman WT: Adenocarcinoma of the uterine corpus. *Current Opinion in Obstetrics and Gynecology*, 5(1)80-83, 1993.
243. Creasman WT: Prognostic Significance of hormone receptors in endometrial cancer. *Cancer* 71:1467, February 1993.
244. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL et al: Prognostic factors in early-stage uterine sarcoma: A Gynecologic Oncology Group Study, *Cancer* 71:1702-9, February 1993.
245. Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, and Williams S: Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group Experience. *Cancer* 71:606, January 1993.
246. Barber HRK and Creasman WT: A rational approach to ovarian masses. *Patient Care*, January 14, 1993.

247. Stehman, FB, Bundy BN, Thomas G, Keys HM, d'Ablaing, Fowler WC, Mortel R and Creasman WT: Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. *J Clin Oncol.* 11(8):001-005, August 1993.
248. DiSaia PH, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG, Creasman WT: Hormone replacement therapy in breast cancer. *Letters to the Editor, Lancet* 342:1232, November 1993.
249. Eddy GL, Jenrette JM, and Creasman WT: Effect of radiotherapeutic technique on local control in primary vaginal carcinoma. *Int J Gynecol Can* 1993, 3:399-404.
250. Creasman, William T: Limited Disease: Role of Surgery. *Seminars in Oncology*, Vol. 21, #1, Feb. 1994, pp.79-83.
251. Hoskins WJ, McGuire, WP, Brady, MF, Homesley, HD, Creasman, WT, Berman, M, Ball H and Berek, JS: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. *Am J Obstet Gynecol* 170:974, 1994.
252. Eddy GL, Spiegel GW and Creasman WT: Adverse effect of electrosurgical loop excision on assignment of FIGO stage in cervical cancer: Report of Two Cases. *Gyn Oncol* 55:313-317, 1994.
253. Creasman WT: Second-look laparotomy in ovarian cancer. *Gyn Oncol* 55(3):122, December 1994.
254. Mackey SE and Creasman WT: Ovarian Cancer Screening. *J Clin Oncology* 13(3): 783, 1995.
255. Eddy GL, Manetta A, Alvarez RD, Williams L, Creasman WT: Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: A gynecologic Oncology Group pilot study. *Gyn Oncol* 57(3):412-416, 1995
256. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, and Woodward J: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. *J Clin Oncol* 13 (7):1589-1599, 1995
257. Creasman WT: New Gynecologic Cancer Staging (editorial). *Gynecol Oncol* 58:159-164, 1995

258. Clarke-Pearson DL, DeLong ER, Chin N, Rice R, Creasman WT: Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. *Arch Surg* 123(5):42-5, 1995
259. Creasman WT: Gynecologic cancer staging. *Internat J Gynecol Obstet* 50:215-6, 1995
260. DiSaia PJ, Grosen EA, Odicino, Cowan B, Pecorelli S, Wile AG, Creasman WT: Replacement therapy for breast cancer survivors. *Cancer* 76:2075-8, 1995
261. Creasman, WT: Selective lymphadenectomy: Facts and fallacies. Point-Counterpoint. *Transactions of the American Gynecological and Obstetrical Society* 13:122-126, 1995
262. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B: Tamoxifen in platinum-refractor ovarian cancer: A gynecologic oncology group ancillary report. *Gynecol Oncol* 62:4-6, 1996
263. Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD: A phase II trial of prolonged oral etoposide as second line therapy for advanced and recurrent endometrial carcinoma. *Gynecol Oncol* 63:101-104, 1996
264. Creasman WT: Hormone replacement therapy and endometrial cancer. *CME J Gynecol Oncol* 1:46-50, 1996.
265. Creasman WT: Hormone replacement therapy in breast cancer. *CME J Gynecol Oncol* 1:64-66, 1996.
266. Creasman WT (editor). Hormone replacement therapy and cancer. *CME J Gynecol Oncol* volume 1, 1996, pp 5-74
267. Creasman WT: Endometrial cancer: Incidence, prognostic factors, diagnosis, and treatment. *Semin Oncol* 24(suppl 1):S1-140-S1-150, 1997
268. Creasman WT: Commentary. Taylor PT, Andersen WA, Rice LW: Carcinosarcoma of the uterus, clinical stage I; p. 480-485. In: Winchester DP, Brennan ME, Dodd GD, Henson DE, Kennedy BJ, Steele GD Jr., Wilson J. Frank (eds) *Tumor Board Case Management*. Philadelphia: Lippincott-Raven, 1997, p 884,
269. Creasman WT: Commentary. Lewis JL Jr,: Stage I uterine cancer with positive peritoneal washings; p. 486-489. In: Winchester DP, Brennan ME, Dodd GD, Henson DE, Kennedy BJ, Steele GD Jr., Wilson J. Frank (eds) *Tumor Board Case Management*. Philadelphia: Lippincott-Raven, 1997, p 888.
270. Creasman WT: Ovarian cancer screening. *ACOG Clinical Review* 2:1, 1997

271. Creasman WT, Phillips JL, Menck HR: The National Cancer Data Base report on early stage invasive vulvar carcinoma. *Cancer* 1997; 80:505-13.
272. Williams L, Brunetto VL, Yordan E, DiSaia PH, Creasman WT: Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: A gynecologic oncology group study. *Gynecol Oncol* 1997;66:171-178
273. Creasman, WT: Evaluating risks of ERT in women who've had cancer. *Contemporary Ob/Gyn* 42:87, 1997.
274. Creasman WT, Zaino RJ, Major FJ, DiSaia PJ, Hatch KD, Homesley HD: Early invasive carcinoma of the cervix (3 to 5 mm invasion): Risk factors and prognosis. A Gynecologic Oncology Group study. *Am J Obstet Gynecol* 178:62-5, 1998.
275. Creasman WT, Phillips JL, Menck HR: The National Cancer Data Base report on cancer of the vagina. *Cancer* 83:1033-40, 1998.
276. Benedet J, Odicino F, Maisonneuve P, Severi G, Creasman W, Shepherd J, Sideri M, Pecorelli S: Carcinoma of the cervix uteri. *J Epidemiology and Biostatistics* 3:1-2, 1998.
277. Creasman W, Odicino F, Maisonneuve P, Benedet J, Shepherd J, Sideri M, Pecorelli S: Carcinoma of the corpus uteri. *J Epidemiology and Biostatistics* 3:35-61, 1998.
278. Pecorelli S, Odicino F, Maisonneuve P, Creasman W, Shepherd J, Sideri M, Benedet J: Carcinoma of the fallopian tube. *J Epidemiology and Biostatistics* 3:63-74, 1998.
279. Pecorelli S, Odicino F, Maisonneuve P, Creasman W, Shepherd J, Sideri M, Benedet J: Carcinoma of the ovary. *J Epidemiology and Biostatistics* 3:75-102, 1998
280. Shepherd J, Sideri M, Benedet J, Maisonneuve P, Severi G, Pecorelli S, Odicino F, Creasman W: *J Epidemiology and Biostatistics* 3:103-109, 1998
281. Shepher J, Sideri M, Benedet J, Maisonneuve P, Severi G, Pecorelli S, Odicino F, Creasman W: Carcinoma of the vulva. *J Epidemiology and Biostatistics* 3:111-127, 1998
282. Creasman W, Odicino F, Maisonneuve P, Benedet J, Sideri M, Pecorelli S, Shepherd J: Gestational trophoblastic disease. *J Epidemiology and Biostatistics* 3:129-135, 1998

283. Creasman WT: Is there an association between hormone replacement therapy and breast cancer? *J Womens Health* 7:1231-46, 1998
284. Pecorelli S, Benedet L, Creasman WT, Shepherd JH on behalf of the 1994-1997 FIGO Committee on Gynecologic Oncology: FIGO staging of gynecologic cancer. *Int J Gynecol Obstet* 64:5-10, 1999.
285. Creasman WT, Phillips JL, Menck HR: A survey of hospital management practices for vulvar melanoma. *J Am Coll Surg* 188:670-675, 1999
286. Creasman WT, DeGeest K, DiSaia PJ, Zaino RJ: Significance of true surgical pathologic staging: A Gynecologic Oncology Group study. *Am J Obstet Gynecol* 181:31-4, 1999
287. Creasman WT, Ettinger B: Controversies in ob/gyn. Should ERT be prescribed for women who have had breast cancer? *Contemporary Ob/Gyn* 44:41-55, 1999
288. Creasman, WT: Stage IA cancer of the cervix: Finally some resolution of definition and treatment? *Gynecol Oncol* 74:163-164, 1999
289. Creasman, WT: Prognostic significance of the size of residual tumor and related prognostic factors. *CME J Gynecol Oncol* 4:51-53, 1999
290. Brewster WR, DiSaia PJ, McGonigle KF, Grosen EA, Kuykendall JL, Creasman WT: An experience of estrogen replacement therapy in breast cancer survivors. *Int J Fertil Women's Med* 44:186-92, 1999
291. Creasman WT: Cancer detection: the importance of Pap smear screening. *Contemporary Ob/Gyn* 44:68-71, 1999
292. Creasman WT: HRT and women who have had breast or endometrial cancer. *J Epidem Biostat* 4:217-225, 1999
293. Hoskins WJ, Creasman WT, Gershenson DM, Montz FJ, Rubin SC, Schwartz PE: Managing ovarian cancer: A roundtable discussion. *OBG Management*, April 2000, pages 58-115.
294. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz APM, Ngan HYS, Sideri M, Pecorelli S: Carcinoma of the cervix uteri. *J Epidem Biostat* 6:5-44, 2000
295. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz APM, Ngan HYS, Sideri M, Pecorelli S: Carcinoma of the corpus uteri. *J Epidem Biostat* 6:45-86, 2000

296. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HYS, Sideri M, Pecorelli S: Carcinoma of the fallopian tube. *J Epidem Biostat* 6:87-103, 2000
297. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HYS, Sideri M, Pecorelli S: Carcinoma of the ovary. *J Epidem Biostat* 6:107-138, 2000
298. Beller U, Sideri M, Maisonneuve P, Benedet JL, Heintz APM, Ngan HYS, Pecorelli S, Odicino F, Creasman WT: Carcinoma of the vagina. *J Epidem Biostat* 6: 139-152, 2000
299. Beller U, Sideri M, Maisonneuve P, Benedet JL, Heintz APM, Ngan HYS, Pecorelli S, Odicino F, Creasman WT: Carcinoma of the vulva. *J Epidem Biostat* 6: 153-174, 2000
300. Ngan HYS, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz APM, Pecorelli S, Sideri M, Creasman WT: Gestational trophoblastic disease. *J Epidem Biostat* 175-184, 2000
301. Creasman WT: Cancer detection: gynecological implications of tamoxifen use. *Contemp Ob/Gyn* 45:99-100, 2000
302. Creasman WT: Estrogen and endometrial cancer. *CME J Gynecol Oncol* 5:204-207, 2000
303. Creasman WT: Estrogen and breast cancer. *CME J Gynecol Oncol* 5:208-211, 2000.
304. Bösze P (ed), Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJS, Vermorken JB, Wells, Wilbanks GD: Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. *Eur J Gynaec Oncol* 21:513-526, 2000.
305. Geier CS, Wilson M, Creasman W: Clinical evaluation of atypical glandular cells of undetermined significance. *Am J Obstet Gynecol* 2001;184:64-9
306. Smith RA, von Eschenbach AC, Wender R (for the ACS Prostate Cancer Advisory Committee); Levin B, Byers T, Rothenberger D, Brooks D (for the ACS Colorectal Cancer Advisory Committee); Creasman W, Cohen C, Runowicz C, Saslow D (for the ACS Endometrial Cancer Advisory Committee), Cokkinides V, Eyre H: American Cancer Society guidelines for the early detection of cancer: prostate, colorectal, and endometrial cancers. *CA Cancer J Clin* 2001;51:38-75.

307. Hurteau JA, Blessing JA, DeCesare SL, Creasman WT: Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2001; 82:7-10.
308. Creasman WT: Cancer and pregnancy: Bulletti C, de Ziegler D, Guller S, Levitz M (eds) *Human Fertility and reproduction: the oocyte, the embryo, and the uterus*. *Annals of the New York Academy of Sciences* 943:281-286, 2001
309. Creasman,WT: Is this a way to choose a char?. *Academic Med* 76:1032-1034, 2001.
310. Yakout HH, Bissada NK, Fahmy W, Creasman W, Fraig M, Hull GW: Synchronous bilateral chromophobe cell renal carcinoma. *J Urol* 166:1826, 2001
311. Blackwood MM, Creasman WT, Speroff L: Postmenopausal hormone therapy: informed patients, shared decisions. *Women's Health in Primary Care (supplement)*, October 2001, page 28-34
312. Creasman WT: Controversies in FIGO staging of corpus cancer. *CME J of Gynecol Oncol* 6:257-259, 2001
313. Plaxe SC, Blessing JA, Bookman MA, Creasman WT: Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study. *Gynecol Oncol* 84:32-35, 2002
314. Creasman, WT: HRT use after breast cancer. *Contemporary ob/gyn* 14:16-32, 2002
315. Creasman WT: Distinguished Professor Series: Estrogen and Cancer. *Gynecol Oncol* 86:1-9, 2002
316. Creasman WT: Current concepts in ovarian management. *Best practice and Research. Clinical Obstet Gynecol* 2002;16(4) 448-609
317. Creasman WT: Is LVSI a prognostic factor in early stage cervical cancer **(abstract)**. *Int J Gynecol Cancer* 2002;12:602
318. Trimble E, Berry D, Gore M, Kavanagh J, Cohen C, Pecorelli S, Creasman W, Mason P, Heinze P: Discussion: current issues in the design of ovarian cancer treatment trials. *Gynecol Oncol* 88:S122-S123, 2003
319. Landen CN Jr, Mathur SP, Richardson MS, Creasman WT: Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. *Am J Obstet Gynecol* 2003; 188:1174-6

320. Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT: Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. *Gynecol Oncol* 2003;91:486-493
321. Ngan HY, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Pecorelli S, Creasman WT: Gestational trophoblastic diseases. *Int J Gynaecol Obstet* 2003;83 Suppl 1:167-74
322. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S: Carcinoma of the ovary. *Int J Gynaecol Obstet* 2003;83 Suppl 1:135-66
323. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S: Carcinoma of the Fallopian tube. *Int J Gynaecol Obstet* 2003;83 Suppl 1:119-33
324. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the corpus uteri. *Int J Gynaecol Obstet* 2003;83 Suppl 1:79-118
325. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. *Int J Gynaecol Obstet* 2003;83 Suppl 1:41-78
326. Beller U, Maisonneuve P, Benedet JL, Heintz AP, Ngan HY, Pecorelli S, Odicino F, Creasman WT: Carcinoma of the vagina. *Int J Gynaecol Obstet* 2003;83 Suppl 1:27-39
327. Beller U, Maisonneuve P, Benedet JL, Heintz AP, Ngan HY, Pecorelli S, Odicino F, Creasman WT: Carcinoma of the vulva. *Int J Gynaecol Obstet* 2003;83 Suppl 1:7-26.
328. Creasman WT, Kohler, MF: Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? *Gynecol Oncol* 2004;92:525-529
329. Creasman WT, DiSaia PJ: Analyzing the HABITS data: Is HT safe in women with previous breast cancer? *OBG Management* 16:14-16,2004
330. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P: Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. *Gynecol Oncol* 2004;95:593-596.
331. Creasman WT: Concerns about published data from estrogen-progestin (HT) arm of the WHI. Letter to the editor. Reply. *Am J Obstet Gynecol* 2005;192:333-8

332. Creasman WT: Vaginal cancers. *Cur Opin Obstet Gynecol* 2005;17:71-76 (reprinted in *Postgraduate Obstet Gynecol* 2005;25:1-7)
333. Creasman WT: Breast cancer: the role of hormone therapy. *Semin Reprod Med.* 2005;23:167-71.
334. Mathur SP, Mathur RE, Creasman WT, Underwood P and Kohler M. Early diagnosis of cervical cancer: Beyond HPV testing. *Disease Markers* 2005;21:1-9.
335. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PB, Kohler M, Creasman WT: Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B. *Gynecol Oncol* 2005;98:467-483.
336. Creasman WT: Hormone replacement therapy after cancers. *Curr Opin Oncol* 2005; 17:493-499
337. Beller U, Quinn MA, Benedet JL, Creasman WT, Ngan HYS, Maisonneuve P, Percorelli S, Odicino F, Heintz APM: Carcinoma of the Vulva, *Int J Gynecol Obstet* 2006;95 (supplement 1):S7-28
336. Beller U, Benedet JL, Creasman WT, Ngan HYS, Quinn MA, Maisonneuve P, Percorelli S, Odicino F, Heintz APM: Carcinoma of the Vagina, *Int J Gynecol Obstet* 2006;95 (supplement 1):S29-42
337. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz APM, Ngan HYS, Percorelli S: Carcinoma of the Cervix Uteri, *Int J Gynecol Obstet* 2006;95 (supplement 1):S43-104
338. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz APM, Ngan HYS, Percorelli S: Carcinoma of the Corpus Uteri, *Int J Gynecol Obstet* 2006;95 (supplement 1):S105-144
339. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HYS, Percorelli S, Beller U: Carcinoma of the Fallopian Tube, *Int J Gynecol Obstet* 2006;95 (supplement 1):S145-160
340. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HYS, Percorelli S, Beller U: Carcinoma of the Ovary, *Int J Gynecol Obstet* 2006;95 (supplement 1):S161-192
341. Ngan HYS, Odicino F, Maisonneuve P, Creasman WT, Beller U, Quinn MA, Heintz APM, Percorelli S, Benedet JL: Gestational Trophoblastic Neoplasia, *Int J Gynecol Obstet* 2006;95 (supplement 1):S193-204
342. Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D: Treatment of ("bulky") stage IB cervical cancer with or without

neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group. *Gynecol Oncol* 106:362-369, 2007

343. Kohler MF, Creasman WT. Controversies Surrounding lymphadenectomy and postoperative radiotherapy in treatment of carcinoma of endometrium. *Future Oncol*. 2008; 4(3).

344. Batchelor EC , Watkins JM, Creasman WT, Kohler MF, Sinha D, Jenrette JM: The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma, *Eur J Obstet Gynecol Rep Biol*, 2008 141 (2): 163-168

CHAPTERS

1. Creasman, WT: In Sciarra (89) **Gynecology and Obstetrics: Surgical Treatment of Endometrial Carcinoma**.
2. Merrill JA and Creasman WT: (89)Danforth's **Obstetrics and Gynecology**, Sixth Edition, Chapter 50: Disorders of the Uterine Corpus. JB Lippincott Co. Philadelphia.
3. Creasman, WT: Nonresectable adenocarcinoma of ovary which shrinks during chemotherapy. Clinical Problems, Injuries and Complications of Gynecologic Surgery, David H. Nichols, Ed., 2nd Edition, Chapter 79, p. 262, 1988.
4. Creasman WT: Surgical treatment of endometrial carcinoma, *Gynecol and Obstet Ed Sciarra JJ, Vol 4, Chapter 19, J. B. Lippincott Co., Philadelphia, 1989*.
5. Creasman WT and Eddy GL: Critical analysis of prognostic factors of ovarian cancer. Multinodal treatment of ovarian cancer. Editors: Pier Franco Conte, Nicola Ragni, Riccardo Ross, Jan B. Vermorken, Vol. 30, 1989.
6. Creasman WT and Eddy GL: Prognostic factors in relationship to second-look laparotomy in ovarian cancer. *Bailliere's Clinical Obstetrics and Gynecology*, 3(1):183, 1989.
7. Creasman, WT and Soper JT: In **Ovarian Cancer: Biological and Therapeutic Challenges**, Edited by F. Sharp, WP Mason, RE Leake, Chapter 21, Tumour markers and the adnexal mass, Chapman and Hall Medical, 1990
8. Creasman, WT and Eddy, GL: In **Ovarian Cancer: Biological and Therapeutic Challenges**, Edited by F. Sharp, WP Mason, RE Leake, Chapter 28, Single versus multiple agent regimens, Chapman and Hall Medical, 1990.

9. Merrill JA and Creasman WT: In **Danforth's Obstetrics and Gynecology, Sixth Edition**, Disorders of the Uterine Corpus, Chapter 50, JB Lippincott, 1990, p. 1023.
10. McGuire, WP, Arseneau JC, Blessing JA, Hatch KD, Given FT, DiSaia PI, Creasman WT, Teng NM: A randomized trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study, in Bunn PA, Canetta R, Ozols RF, Rosencweig (eds), **Carboplatin (JM-8) Current Perspectives and Future Directions Saunders, Philadelphia, 1990, p 130.**
11. Creasman, WT: In Bosze, Peter, Eckhardt, Sandor, and Gati, Istvan: Recent Advances in Gynaecologic Oncology, Proceedings of the 1st Budapest Symposium, 1990: Radical hysterectomy and pelvic node dissection: How far should we go?
12. Creasman WT: In **Danforth's Obstetrics and Gynecology, Sixth Edition**, Malignant Lesions of the uterine corpus, Chapter 50, p. 1040.
13. Creasman WT and Eddy GL: Endometrial Carcinoma, Quilligan and Zuspan, editors, **Current Therapy in Obstetrics and Gynecology**, W.B. Saunders Co., 1990.
14. Smith EB and Creasman WT: Preinvasive and Invasive Cervical Neoplasia, Chapter 186, P. 1132 in **Principles and Practice of Medical Therapy in Pregnancy, Ed. Norbert Gleicher, 2nd Edition**, Appleton and Lange, 1992.
15. Creasman WT and Weed JC Jr.: Carcinoma of endometrium (FIGO Stages I and II): Clinical features and management. Chapter 49 in **Gynecologic Oncology, Ed. Malcolm Coppleson, Vol. 2, Churchill Livingstone, 1992.**
16. Creasman WT: Adenocarcinoma of the uterine corpus in **Gynecologic Oncology, Robert C. Knapp and Ross S. Berkowitz, eds. 2nd Edition, McGraw-Hill, Inc., 1993.**
17. Creasman WT: Evaluation of debulking surgery at second-look laparotomy in **Ovarian Cancer 2, Edited by F. Sharp, W. P. Mason, W Creasman, Chapman and Hall Medical, London, 1992, p. 375-383.**
18. Creasman WT: Hormonal Replacement Therapy in the Cancer Patient. **Hormone Replacement Therapy, Edited by Donald P. Swartz, Williams and Wilkins, Baltimore, 1992, pg.235-47.**
19. Creasman WT: Endocrine Replacement Therapy after Treatment of Gynecologic Malignancy in **Surgical Gynecologic Oncology, edited by E. Burghardt, Georg Thieme Verlag Stuttgart, 1993.**

20. Creasman WT: Adenocarcinoma of the uterine corpus. **Cancer Medicine, 3rd edition, James F. Holland, Editor**, Lea and Fibesger, 1993
21. Eddy GL and Creasman WT: Neoplasms of the Fallopian Tube, **Cancer Medicine, 3rd edition, James F. Holland, Editor**, Lea and Fibesger, 1993.
22. Creasman WT: Surgical Treatment of Endometrial Carcinoma, **Gynecology and Obstetrics**, editor John J. Sciarra, M.D., Ph.D., J. B. Lippincott Co., Philadelphia, 1993.
23. Eddy, GL, Manetta A, Alvarez RD, Williams L and Creasman WT: Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage 1b bulky cervical cancer: A GOG group pilot study. **Adjuvant Therapy of Cancer VII.**, Sydney E. Salmon, Ed., J. B. Lippincott Co., 1993.
24. Creasman, WT: Disorders of the Uterine Corpus, Chapter 49,p. 925, **Danforth's Obstetrics and Gynecology, Seventh Edition**, James R. Scott, Philip J. DiSaia, Charles B. Hammond and William N. Spellacy, J. B. Lippincott Co., 1994.
25. Creasman, WT: Cervical Carcinoma. **Current Therapy in Obstetrics and Gynecology 4**, editors Zuspan/Quilligan,W. B. Saunders Co., Philadelphia, 1994, p.171
26. Creasman, WT: Endometrial Cancer: Hormone Influences, **Women's Health Today**, Pipkin DR, Peddle LJ ed. Parthenon Publishers Group NY, London, 1994, p.129.
27. Creasman, WT: Managing side effects from tamoxifen: **Cancer Consultations, Vol. 1**, editors Martin D. Abeloff and Robert E. Wittes, PRR, Huntington, NY 1994, p.31
28. Creasman WT: Nonresectable adenocarcinoma of ovary which shrinks during chemotherapy. In editors David H. Nichols and John O. L. DeLancy, **Clinical Problems, Injuries and Complications of Gynecologic and Obstetric Surgery**, 3rd Edition, Williams and Wilkins, 1995.
29. Mackey SE, Creasman WT: Screening: Potential benefits and adverse consequences. In Lawton FG, Neijt JP, Swenerton KD (eds). **Epithelial Cancer of the Ovary**. London: BMJ Publishing Group, 1995, pp 36 -58
30. Creasman WT: Endometrial cancer in Fischer DS (ed) **Follow-up of Cancer: A Handbook for Physicians**, 4th edition, Lippincott-Raven, 1996. p. 80

31. Morrow CP, Creasman WT, Homesley H, Yordan E, Park R, Bundy B: Recurrent in endometrial carcinoma as a function of extended surgical staging data. In Morrow CP, Smart GE (eds) *Gynecologic Oncology*, Springer-verlag, NY, 1985, p 147-53.
32. Estrogenos y Cancer de Marma in *Avances en la atencion integral al climacteria*. Eds: Cano A, Bonilla-Musoles F, Tortajada M and Julia MD. Impreso en Graficas Hurtado p 489-98, Valencia 1998.
33. Jennings TS, Creasman WT: Effects on the reproductive tract: Clinical aspects. In Lindsay R, Dempster D, Jordan VC, **Estrogens and Antiestrogens**, Lippincott-Raven Publishers, Philadelphia, 1997, p 223.
34. Creasman WT: Screening for gynecological cancer. In **New Insights in Gynecology and Obstetrics: Research and Practice. Proceedings of the FIGO World Congress on Gynecology and Obstetrics**, Copenhagen, August 1997, Parthenon Publishing, United Kingdom, 1998, p. 67-71.
35. Creasman WT: Surgical treatment of endometrial carcinoma, In Sciarra JJ (ed), *Gynecol and Obstet Vol 4*, Chapter 19, J. B. Lippincott Co., Philadelphia, 1998.
36. Creasman WT, Kohler MF: Adenocarcinoma of the endometrium, In O'Brien, PMS (ed) **Yearbook of Obstetrics and Gynaecology**, Royal College of Obstetricians and Gynecologists Press, 2000, p 344-354
37. Creasman WT: Cancer and Pregnancy, In Bulletti C, DeZiegler D, Guller S, Levitz M (eds) **Human Fertility and Reproduction. The Oocyte, the Embryo, and the Uterus**. Annals of the New York Academy of Sciences, volume 943, 2001, pp 281-286.
38. Creasman WT: Surgical management of endometrial cancer In Sciarra J (ed) **Gynecology and Obstetrics**, Lippincott Williams and Wilkins, 2002, chapter 19.
39. Creasman WT: Cancer in Pregnancy In Gilstrap LC, Cunningham FE, VanDorsten JP (eds) **Operative Obstetrics**, McGraw-Hill, New York, chapter 24, 2002
40. Creasman WT: Malignant tumors of the uterine corpus In Rock JA, Jones HW (eds) **TeLinde's Operative Gynecology**, 9th edition, Lippincott Williams and Wilkins, chapter 47, 2003
41. Creasman WT, Kohler, MK: Estrogen replacement therapy in the endometrial- and breast-cancer-patient In Studd J (ed) **The Management of the Menopause**, Parthenon Publishing Group, New York, NY 2003, 3rd edition, Chapter 9, page 77.

ABSTRACTS

Creasman WT, DiSaia PJ, Boronow RC, Morrow CP, Blessing J: Follow up of individual therapy in patients with adenocarcinoma of the endometrium. *Gynecol Oncol* 10:358, 1980.

Berman M, Keys H, Creasman WT, DiSaia PJ, Blessing JA, Bundy B: Periaortic lymph node metastases in cervical carcinoma. SGO, 1983

Abdulhaz G. DiSaia PJ, Creasman WT, Homesley H, Whisnant J: Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies. *Am J Clin Oncol* 3:167, 1984

Morrow CP, Creasman WT, Homesley H, Wilbanks G, Bundy B: Recurrence in endometrial carcinomas as a function of extended surgical staging date. *Am Radium Soc* 7:114, 1984

Silverberg SE, Major F, Morrow P, Blessing J, Creasman WT, Curry J: A preliminary analysis of prognostic factors in uterine sarcoma. *Int Soc Gynecol Pathol*, 1986

Beecham J, Blessing J, Creasman WT, Hatch K: Responsiveness to tamoxifen in 107 patents treated with cytoreductive surgery and front line chemotherapy. *Int Gynecol Can Soc*, Amsterdam, 1987

Curry S, Blessing J, DiSaia, P, Creasman W, and Twiggs L: A prospective randomized comparison of methotrexate, Actinomycin-D and Chlorambucil (MAC) vs. Modified Bagshawe Regiment in "Poor Prognosis" Gestational trophoblastic disease. GOG Study. (Abstract) International Meeting of Trophoblastic Neoplasia, Fall, 1986 & SGO February 1987.

Morrow CP, Bundy B, Creasman WT, Homesley H: A randomized study of adriamycin adjuvant chemotherapy for patients with high risk stage I and II endometrial carcinoma. *Int Gynecol Can Soc.*, Amsterdam, 1987

Silverberg SE, Major F, Morrow P, Blessing J, Creasman WT, Curry J: Malignant mixed mesodermal tumor of the endometrium. *U.S.-Canadian Academy of Pathology*, 1988

Beecham J, Blessing J, Creasman W, Hatch K: Tamoxifen responsiveness, hormone receptors and tumor grade SGO, 1988

Beecham J, Blessing J, Creasman W, Hatch K: Tamoxifen is effective as second line therapy for certain patients with advanced, chemotherapy-resistant epithelial ovarian cancer: A GOG Study of 105 patients. *Proceedings of ASCO Vol. 7*, March 1988

McGuire WP, Arseneau JC, Blessing JA, Given FT, Hatch KD, Creasman WT, DiSaia PJ and Teng NN: Randomized comparison of carboplatin (CP) and Iproplatin (IP) in

advanced squamous carcinoma of the uterine cervix (SCUC): A GOG Study. Proceedings of ASCO, Vol. 7, March 1988.

Sutton, G, Bundy, B, Delgado, Sevin B, Creasman W, Major F and Zaino R: Ovarian metastases in stage IB cervical carcinoma, GOG, Philadelphia, PA 19107 SGO

McGuire WP, Arseneau J, Blessing JA, Given F T, Hatch KD, Creasman WT, DiSaia PJ and Teng NN: Randomized comparison of carboplatin (CP) and Iproplatin (IP) in advanced squamous carcinoma of the uterine cervix (SCUC): A GOG Study. ASCO, March 1988.

McGuire WP, Arseneau J, Blessing, JA, DiSaia, PJ, Hatch KD, Given FT, Teng NH and Creasman WT: A randomized comparative trial of carboplatin and Iproplatin in advanced squamous carcinoma of the uterine cervix: A GOG Study. J Clin Oncol. #10, 7:1462-8, October 1989.

Delgado G, Bundy BN, Fowler WC, Stehman FB, Sevin B, Creasman WT, Major G, DiSaia PJ, Zaino R: A prospective surgical pathologic study of disease free interval (DFI) stage I squamous carcinoma of the cervix, Society of Gynecological Oncology, 1990

Creasman WT: Pros and Cons of ERT in Cancer Patients: The Debate Continues. Oncology Times Vol XV#4:27, April 1993.

Creasman W, Bundy B, Zaino R, Homesley H and Majors F: Early invasive carcinoma of the cervix with 3-5 mm of invasion—Risk factors and prognosis. Gyn Oncol 52:103,1994, GOG Philadelphia, PA and Buffalo NY

Creasman WT, Bundy B, Zaino R et al: Early invasive carcinoma of the cervix with 3-5 ml of invasion--risk factors and prognosis. Gynecol Oncol 52:103, 1994

Creasman WT, Bundy B, DeGeese K, DiSaia PJ, Zaino, Gynecologic Oncology Group, Philadelphia, Pennsylvania: Stage II Endometrial Cancer: The Inaccuracy of Clinical Staging. Presented at the 26th annual meeting of the Felix Rutledge Society, May 31-June 3, 1995. Gynecol Oncol 59:430-434, 1995

Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD: A phase II trial of prolonged oral etoposide as second line therapy for advanced and recurrent endometrial carcinoma. ASCO 1995

Creasman WT, Bundy BN, DeGlast K, DiSaia P, Zaino R: Stage II adenocarcinoma of the endometrium: Significance of true surgical pathologic staging. Gynecol Oncol 59:430, 1995

Brewster WR, DiSaia PJ, Groten EA, Kuykendall JL, McGonigle KF, Creasman WT:
Estrogen replacement therapy in breast cancer survivors. *Gynecol Oncol* 66:348, 1997

Creasman WT: Is LVSI a prognostic factor in early stage cervical cancer

AUDIOVISUAL PRODUCTIONS

1. ACOG Update: Vulvar Disease
2. ACOG Update: Ovarian Cancer
3. Audio Digest: Advanced Colposcopy
4. Perspectives in Gynecology: Modified Partial radical Vulvectomy with Superficial Inguinal Lymphadenectomy, 1981.
5. OB-GYN Illustrated: Selective Lymphadenectomy and Hysterectomy for Carcinoma of the Endometrium, 1985.
6. Video Journal of OB/GYN: Invasive Cervical Cancer: Type III Radical Hysterectomy and Pelvic Lymphadenectomy, 1989.
7. Video Journal of OB/GYN: Papanicolaou Smear: Screening Protocol and Colposcopic Assessment of Abnormal Findings, 1989.
8. Video Journal of OB/GYN: Pap Smear Part I: Basic Technique, 1990.
9. Video Journal of OB/GYN: Pap Smear Part III: Evaluation of the Abnormal Pap Smear,
Vol IV: January 1991
10. Video Journal of OB/GYN: Long-Term Reversible Contraception: Clinical Perspectives Current Concepts in the Treatment of Endometrial Cancer: Part I. WT Creasman and PJ DiSaia, V:4, July 1992.
11. Maximum Debulking of Advanced Ovarian Carcinoma, 1991
12. Estrogen's Cancer in Audio-Digest Obstetrics/Gynecology, *Topics in Breast Cancer*, Volume 54, Issue 23, December 2007.

BOOKS

DiSaia PJ and Creasman WT: Clinical Gynecologic Oncology, 1st - 7th Edition, Mosby Year Book, St. Louis 1980 -2007, with Spanish and Italian translations

Sharp F, Mason WP, Creasman WT: Ovarian Cancer 2, Chapman & Hall Medical, London, 1992.

INTERNET CONTRIBUTIONS

1. Commentary: HRT in breast cancer, breastlink.com, August 2000
2. Malignant vulvar lesions. eMedicine, April 5, 2002,
<http://www.emedicine.com/med/topic3296.htm>
3. Creasman WT: Endometrial Carcinoma in Kavanagh JJ, Talavera F, Barnes AD et al (eds). **eMedicine Journal** volume 5, number 12, December 14, 2004
4. Endometrial carcinoma e-medicine, published July 2007
5. Malignant Vulvar Lesions e-medicine, published July 2007